Synthetic Nanoparticles for Vaccines and Immunotherapy by Rakhra, Kavya et al.
Synthetic Nanoparticles for Vaccines and Immunotherapy
Darrell J. Irvine1,2,3,4,5,*, Melissa C. Hanson1,2, Kavya Rakhra2, and Talar Tokatlian2
1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 
02139, USA
2David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
Cambridge, MA 02139, USA
3The Ragon Institute of MGH, MIT, and Harvard, 400 Technology Square, Cambridge, MA 02139, 
USA
4Department of Materials Science & Engineering, Massachusetts Institute of Technology, 
Cambridge, MA 02139, USA
5Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
1 INTRODUCTION
1.1 Progress and challenges in the new age of engineering immunity
The immune system plays a critical role in our health. No other component of human 
physiology plays a decisive role in as diverse an array of maladies, from deadly diseases 
with which we are all familiar to equally terrible esoteric conditions: HIV, malaria, 
pneumococcal and influenza infections; cancer; atherosclerosis; autoimmune diseases such 
as lupus, diabetes, and multiple sclerosis. The importance of understanding the function of 
the immune system and learning how to modulate immunity to protect against or treat 
disease thus cannot be overstated. Fortunately, we are entering an exciting era where the 
science of immunology is defining pathways for the rational manipulation of the immune 
system at the cellular and molecular level, and this understanding is leading to dramatic 
advances in the clinic that are transforming the future of medicine.1,2 These initial advances 
are being made primarily through biologic drugs– recombinant proteins (especially 
antibodies) or patient-derived cell therapies– but exciting data from preclinical studies 
suggest that a marriage of approaches based in biotechnology with the materials science and 
chemistry of nanomaterials, especially nanoparticles, could enable more effective and safer 
immune engineering strategies. This review will examine these nanoparticle-based strategies 
to immune modulation in detail, and discuss the promise and outstanding challenges facing 
the field of immune engineering from a chemical biology/materials engineering perspective.
1.1.1 Key cellular actors in the immune system—A brief summary of the cellular 
players in the immune response is worthwhile to preface the many immunomodulatory 
approaches described in this review. The immune system can be viewed at a high level as a 
*Address correspondence to: Darrell J. Irvine, 500 Main St, 76-261, Cambridge, Massachusetts 02139, USA. Phone: (617) 452-4174; 
djirvine@mit.edu. 
HHS Public Access
Author manuscript
Chem Rev. Author manuscript; available in PMC 2015 December 23.
Published in final edited form as:
Chem Rev. 2015 October 14; 115(19): 11109–11146. doi:10.1021/acs.chemrev.5b00109.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
collection of mobile cells that include members that traffic throughout the body in search of 
invading pathogens as well as cells that reside as sentinels at portals of entry (i.e. the 
airways, skin, gastrointestinal tract, etc.).3 These cells belong to one of two major arms, the 
innate immune system and adaptive immune system. Innate immune cells such as 
neutrophils and macrophages are poised to rapidly respond to pathogen invasion, expressing 
receptors that recognize conserved molecular motifs characteristic of bacteria, viruses, and 
fungi, to quickly phagocytose (internalize) microbes and secrete reactive oxygen species or 
cytokines that provide an immediate response to invading pathogens. The adaptive immune 
system is comprised of T-cells and B-cells, including CD4+ helper T-cells that secrete 
cytokines to direct the functions of innate cells, killer cells, and B-cells; and CD8+ killer T-
cells that recognize and destroy infected or transformed cells. B-cells play a canonical role 
in vaccine responses by producing antibodies that bind to and neutralize the ability of 
microbes to invade host cells and/or promote their phagocytosis. The adaptive immune 
system is so named because of the clonal nature of T and B lymphocytes– each T-cell and 
B-cell expresses a unique T-cell receptor or B-cell receptor, respectively, which is generated 
in part by a process of stochastic DNA recombination, enabling the pool of lymphocytes the 
potential to recognize any microbial antigen they may encounter.4 When a T- or B-cell binds 
an antigen (essentially, any biological molecule from a microbe that is recognized by a T-
cell receptor (TCR) or B-cell receptor (BCR)), this triggers massive proliferation of the 
antigen-specific cell, generating a pool of effectors within ~7 days following exposure. 
These effector T-cells and B-cells play an important role in backing up innate immune 
defenses to clear the invading pathogen. Following pathogen clearance, the majority of these 
cells (~90%) undergo programmed cell death, leaving a small pool of differentiated memory 
cells that can remain for the lifetime of the individual, to provide rapid recall protection if 
the same microbe is ever encountered again.5 A final key group of immune cells are the 
antigen presenting cells (APCs), and particularly a critical APC known as the dendritic cell, 
which is responsible for activating naïve T-cells (and in some cases B-cells).6,7 Dendritic 
cells (DCs) are innate-like cells that reside in all peripheral tissues, and which act as 
sentinels, collecting antigens from the surrounding fluid and staying on constant alert for 
“danger signals”- molecular motifs signifying tissue damage or pathogen invasion. DCs and 
other immune cells express a host of receptors that specifically recognize danger signals to 
trigger their activation; the most studied among these receptors are the Toll-like receptors.8 
If activated by danger signals, DCs migrate from their home tissue through the lymphatic 
vessels to local draining lymph nodes, where they physically present antigen to T-cells and 
B-cells. For T-cell activation, this is through the loading of short (8–15 amino acids) peptide 
fragments of antigens into the cleft of major histocompatibility complex (MHC) molecules 
displayed on the DC surface. These peptides are surveyed by the TCRs of T-cells, and on 
finding a cognate peptide, T-cells become activated by the DC to proliferate and carry out 
their effector functions.
The vastly complex set of cellular interactions summarized above (greatly oversimplified) is 
the network of interest to those interested in immune engineering, and in this review we aim 
to summarize the myriad ways in which materials scientists, chemical engineers, 
bioengineers, chemists, and physicists (often in collaboration with immunologists) are using 
nanomaterials as powerful tools to probe or manipulate immune responses for therapeutic 
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ends. To set the stage for the rest of the review, we will briefly discuss two of the areas 
where synthetic nanoparticles have the prospect to play a significant role in the ongoing 
revolution of immunology in medicine– vaccines and active immunotherapy.
1.1.2 Designing new vaccines—Vaccines are pharmaceutical preparations of antigens– 
macromolecules derived from pathogens– which when administered to the body elicit an 
immune response and establish immunologic memory of the antigen, usually in the form of 
long-lived production of antibodies against the antigen.9 A strong case can be made that 
vaccines are the single most impactful medical technology to be developed in history– as 
vaccines have saved hundreds of millions of lives in the past century.10,11 The introduction 
of an effective new vaccine has been repeatedly shown to have an immediate, dramatic 
impact on the frequency of disease in a given population, as illustrated by the annual cases 
of polio and measles in the United States before and after the introduction of their respective 
vaccines (Fig. 1).12,13 Prophylactic vaccines (administered to healthy individuals to protect 
against future exposures) have successfully eradicated or greatly reduced the frequency of 
infectious diseases that, at the beginning of the 20th century, exacted a serious toll in deaths 
and morbidity, including diphtheria, tetanus, measles, polio, smallpox, mumps, rubella, and 
typhoid, to name a few. These successes make the value of an effective vaccine very clear. 
However, successful vaccines remain elusive for a number of important diseases, including 
HIV, tuberculosis, and malaria.10 These diseases share a number of features that are distinct 
from those for which existing vaccine strategies have been successful.14 Successful vaccines 
have been generated primarily for diseases that cause acute infections, and for which the 
natural immune response in a fraction of persons will be protective and establish life-long 
protective immunity, mediated in the vast majority of cases by neutralizing antibodies 
(produced by B-cells and their progeny, plasma cells). By contrast, diseases for which we do 
not yet have an effective vaccine often establish chronic infections, which the immune 
system of unvaccinated individuals is unable to eradicate, and which do not induce 
protective immune memory against re-exposure.15 Further, T-cells, in addition to B-cells, 
are thought to potentially be important in attacking these pathogens.16 This problem 
highlights the challenge facing modern vaccine design– we must develop vaccines that can 
achieve what the natural immune system cannot, potentially employing both arms of 
adaptive immunity.
A second major challenge for current vaccine efforts is the development of effective 
therapeutic vaccines that can treat established disease. Therapeutic vaccines could impact 
not only infectious diseases such as HIV and tuberculosis, but also non-infectious diseases 
such as cancer.17,18 In addition, the possibility of vaccines that shut off immune responses to 
target antigens instead of turning them on has been proposed, as a means to eliminate 
unwanted immune reactions in autoimmune disease and allergies.10 Therapeutic vaccines 
for cancer and autoimmune disease introduce the additional complexity that they aim to 
employ the immune system, which has evolved to deal with infectious disease, to instead 
treat non-infectious disorders.
1.1.3 Capitalizing on the promise of immunotherapy—Vaccines represent an 
intervention with long-established benefits to public health, based on inoculation of the 
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immune system with a target antigen in a way that induces immunological memory to 
protect against future exposures to the source pathogen. However, in the presence of existing 
disease, there are other routes to instructing the immune system to attack malfunctioning or 
tumorigenic cells, broadly termed immunotherapies. Immunotherapies have been pursued 
for a broad range of diseases, but arguably the greatest effort has been invested in the 
development of therapeutics that prime the immune system to attack cancer;2,19,20 for the 
purpose of setting the stage for later discussions in this review, we will focus on this specific 
case as an example of current treatment strategies in the clinic.
A diverse set of approaches has been taken to develop cancer immunotherapies, including 
the administration of therapeutic vaccines, recombinant cytokines, immunomodulatory 
antibodies, small molecule drugs, and adoptively transferred immune cells. Among these 
various approaches, two strategies have recently been proven to be capable of dramatic 
impacts in advanced cancer patients: treatment of patients with so-called checkpoint 
blockade antibodies, and adoptive transfer of chimeric antigen receptor T-cells. Checkpoint 
blockade refers to the use of antibodies that block negative regulatory receptors on T-cells, 
in effect “taking the brakes off” the immune system and allowing endogenous natural 
immune responses against tumors to be unveiled. Two different checkpoint blockade 
treatments targeting different receptors (CTLA-4 and PD-1) have recently been approved by 
the FDA, on the basis of striking clinical trial results in melanoma, renal cell carcinoma, and 
lung cancer (and several additional similar therapeutics seem likely to be approved soon on 
the basis of ongoing trials).5,11,21,22Anti-PD-1 antibodies in particular have shown striking 
tumor regression in a subset of patients, even against traditionally difficult-to-treat tumors 
like non-small cell lung cancer.22 While checkpoint blockade therapies energize the native 
immune response against cancer, adoptive transfer of chimeric antigen receptor (CAR) T-
cells represents true engineering of immune responses: Here, T-cells isolated from the blood 
of patients are genetically engineered to express synthetic receptors (CARs) based on a 
fusion of an antibody binding domain with T-cell signaling domains, replacing the natural 
TCR with a CAR that binds to surface-expressed proteins on target tumor cells. In clinical 
trials of leukemia, CAR therapy has resulted in remarkable tumor regressions, enabling 
complete tumor eradication in ~80% of treated patients.23 These advances provide crucial 
proof of principle that the immune system is capable of safely eliminating massive tumor 
burdens in patients that have no other option, and have signaled the beginning of an 
immunotherapy-led revolution in cancer treatment.
1.2 Guiding principles motivating synthetic nanomaterials in immune engineering
The purpose of this review is to highlight the many ways in which nanoparticle chemistry 
and engineering are being applied to tackle challenges in vaccine development and to build 
on recent successes in immunotherapy. With the exception of cell-based therapies being 
pursued in cancer immunotherapy, all of the immune engineering strategies currently in the 
clinic are based on traditional drug development approaches- antibodies, recombinant 
proteins, small molecule drugs. So what is the inspiration for novel engineered materials for 
this purpose? There are a number of over-arching themes that drive this work, which recur 
throughout this review. Some of these motivating concepts are common to other therapeutic 
areas where nanoparticles are of significant interest, such as cancer nanomedicine or nucleic 
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acid delivery,24 while others are unique to the distributed cellular network that makes up the 
immune system. First is the principle that immunomodulatory compounds must reach their 
target cell types to exert their effects, and nanoparticle carriers can greatly increase the 
localization of these drugs in target lymphoid tissues or within specific immune cells, and 
thereby dramatically increase their potency.25 With this enhanced tissue and/or cellular 
targeting, these engineered vaccines and immunotherapies can also exhibit greatly enhanced 
safety.14,26–28 While safety is almost always considered secondary to efficacy in animal 
models of immunotherapy, it is the primary driver in clinical prophylactic vaccine 
development. In addition, because many immunomodulatory drugs such as recombinant 
cytokines act on diverse immune cell types, many of these agents have failed as 
systemically-administered treatments even in oncology, due to the severe toxicity of “on-
target but off-tumor” side effects.29–31 Nanoparticle formulations offer the potential of 
making these powerful signaling agents effective for modulating the right target cells at the 
right location, and ablating the severe toxicity often associated with immunomodulators. 
Nanoparticle forms of antigens and immunomodulatory compounds can also change the 
function of these agents– by promoting multivalent receptor crosslinking, by altering 
intracellular processing, by promoting cytosolic delivery, or by physically co-localizing 
synergistic cues within the same intracellular compartment or cell surface site.1 Finally, 
nanomaterials can themselves have intrinsic immunomodulatory function, acting as 
adjuvants or immune potentiators. This last area is just beginning to be explored and offers 
the potential not only for new therapeutics but also may lead to new levels of understanding 
how the immune system defines “danger signals”. A broad range of synthetic nanomaterials 
are being studied as platforms to achieve these goals, and will be discussed throughout the 
review (a non-exhaustive summary of some of the most-studied materials is provided in 
Table 1). Promising preclinical data in these many different strategies for shaping immune 
responses via synthetic materials suggest that nanomaterials will have an important role to 
play in the future of vaccines and immunotherapy.
2 Nanoparticles regulating immunity at the single-cell level
Through years of research, many of the immunological mechanisms through which vaccines 
and immunotherapies interact with the innate and adaptive immune systems at the single cell 
level have been thoroughly characterized. In parallel several advances in chemistry and 
material science have made it possible to engineer synthetic materials to manipulate 
biological functions of cells32. There are three broad strategies that have been pursued to 
date in using nanoparticles to modulate immune responses at the single-cell level: In the first 
approach, nanoparticles are directly attached to or allowed to be internalized by immune 
cells ex vivo, thereby arming these cells for subsequent injection in vivo, where the 
nanoparticle cargo can release drugs that direct immune cell function or impart new 
functionalities to therapeutic cells. A second strategy is to exploit the “natural targeting” of 
nanoparticles to phagocytic cells in vivo, injecting free particles that are scavenged by 
monocytes, macrophages, dendritic cells, or neutrophils in the blood, spleen, liver, bone 
marrow, or other target tissue sites. Finally, so-called “active” targeting has been explored, 
whereby specific ligands or antibodies on the surface of nanoparticles are used to direct 
binding to specific cell targets in vivo. In this section, we discuss examples of these three 
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approaches and various promising nanoparticle-based strategies to target different innate 
immune and adaptive immune populations.
2.1 Targeting the innate immune system
2.1.1 Modulating macrophages and monocytes—Macrophages are a highly 
heterogeneous class of phagocytic cells distributed in all tissues throughout the body such as 
the lungs (alveolar macrophages), liver (Kupffer cells), spleen, and bone marrow. These 
cells differentiate from immature monocytes that are in the bone marrow and blood 
circulation. Macrophages can engulf pathogens and apoptotic cells, process and present 
antigens and release cytokines to initiate and regulate the adaptive immune response. 
Macrophages are amongst the first immune cells to be recruited to sites of tissue injury or 
infection33 and play a central role in mediating inflammation which can either be host 
protective in the short term, or over prolonged periods result in inflammatory pathologies 
like atherosclerosis, inflammatory bowel disease, chronic obstructive pulmonary disorder 
(COPD) and tumor growth and metastasis. As macrophages differentiate, they can acquire a 
spectrum of different phenotypes depending on the factors present in their 
microenvironment. The ends of this spectrum of phenotypes are defined by ‘M1’ or 
classically activated macrophages that mediate host defense against pathogens and anti-
tumor immunity, and ‘M2’ or alternatively activated macrophages that function during 
wound healing and promote tumor growth34. Both M1 and M2 macrophages actively 
endocytose and phagocytose material from their surroundings35. Due to their phagocytic 
nature, passive targeting of macrophages with synthetic nanoparticles is easily achieved.36 
As different subsets and phenotypes of macrophages were identified and macrophage 
receptor expression characterized, targeting strategies have also been developed through 
surface engineering of particles with ligands that can bind to specific macrophage receptors.
A first approach to dose phagocytic cells with nanoparticles carrying immunoregulatory 
drugs has been to “feed” macrophages or monocytes with particulate cargo ex vivo, followed 
by injection of the particle-laden cells to allow their homing to tissue sites in vivo. In this 
way, phagocytes can be used as delivery vehicles to transport therapeutics to various disease 
sites since monocytes and macrophages migrate to sites of inflammation.33 The anti-
retroviral (ARV) protease inhibitor idinavir (IDV) was delivered using this strategy with 
promising results in a humanized mouse model of HIV infection (Fig. 2)37 and HIV-induced 
encephalitis.38 To load bone marrow derived macrophages (BMDM) with IDV 
nanoparticles, they were incubated with IDV loaded in a phospholipid nanosuspension. 
Injection of these IDV-loaded BMDMs resulted in higher concentrations of IDV maintained 
in tissues and serum, and led to reduced HIV viral loads and improved CD4:CD8 T-cell 
ratios compared to systemic administration of the free drug.37 While results with 
nanoparticle-loaded macrophages for ARV drug delivery are promising, the clinical 
complexities of cell therapies make it likely that the first clinical testing of nanoparticulate 
ARVs will be done using injection of free nanoparticle forms of these drugs. Commercial 
formulations of polymer-stabilized solid drug nanoparticles of the ARV rilpivarine have 
recently been tested for biodistribution and pharmacokinetic behavior in rats and dogs and 
show lymphoid tissue deposition that suggests uptake by macrophages in vivo following i.v. 
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injection.39 These results set the stage for clinical testing of such formulations as candidate 
long-acting ARV treatments.
Macrophages and monocytes also home to hypoxic regions of tumors.40 Macrophages 
loaded with liposome-encapsulated chemotherapeutics resulted in increased drug delivery to 
tumors compared to systemic administration of liposomes.41 In a model of glioblastoma, 
intra-cranial injection of cyclodextrin-based NPs resulted in their accumulation at tumor 
sites through transport by tumor-associated macrophages (TAMs).42 While it is clear that 
macrophages can be used to enhance the delivery of NPs to tumors, further work is required 
to optimize the in vivo therapeutic efficacy of this strategy.
Passive targeting of macrophages involves injecting particles with optimal shape,43 size and 
surface charge44 systemically to access monocytes and macrophages in specific tissue 
compartments. For optimal phagocytosis, particles require a shape with high length 
normalized curvature43 and a negative surface charge,45 however this can differ with the 
material being used. Depending on the material composition of the nanoparticle and the kind 
of macrophage it interacts with, the size range for particles being phagocytosed can vary 
from 85 nm to 10 µm.46–48 Within this size range, smaller nanoparticles (100–300 nm) are 
internalized less efficiently than larger nanoparticles (2–3 µm).45
The surface charge of nanoparticles also influences their uptake by phagocytic cells. While 
phagocytic cells can take up both cationic and highly anionic particles44, cationic particles 
can cause cytotoxicity due to plasma membrane disruption, production of reactive oxygen 
species (ROS) and inflammatory responses.45,47,49 However, this generalization is not 
universal, since certain anionic nanoparticles can also cause cytotoxicity when internalized 
by macrophage cell lines.50 Ultimately, it is the combination of multiple physical parameters 
including size, surface charge, hydrophobicity and material composition that influence 
cellular uptake and cytotoxicity of nanoparticles.
Following intravenous injection, particulate matter is typically removed from systemic 
circulation by specialized macrophages of the spleen and liver (Kupffer cells) due to the 
open fenestrations of endothelial cells and sinusoids in the spleen and liver resulting in 
greater access of macrophages to circulating blood.51 For example, this strategy was 
recently used to deliver siRNA to silence the regulatory receptor programmed death ligand-1 
(PD-L1) expressed by Kupffer cells and sinusoidal endothelial cells in the liver.52 PD-L1 is 
a ligand for the inhibitory receptor Programmed death-1 (PD-1) expressed on activated T-
cells53 and NK-cells;54,55 binding of PD-1 on lymphocytes to Kupffer cell PD-L1 normally 
restrains T-cell activation/inflammation and maintains a tolerogenic environment in the 
liver.56 Dolina et al. observed that intravenously-injected lipidoid nanoparticles (LNPs) 
carrying PD-L1 siRNA were taken up primarily by Kupffer cells in the liver and 
accumulated around the cell nuclei. This resulted in downregulation of PD-L1 expression 
and increased activation of NK cell and T-cells in the liver that enabled treated animals to 
clear hepatic viral infections (Fig. 3).52 Macrophages in the spleen can also be targeted by 
systemic nanoparticle administration: intravenous administration of CCR2-siRNA 
encapsulated in LNPs resulted in maximal accumulation in the Ly6Chi monocyte 
populations of the spleen and bone marrow. CCR2 is a chemokine receptor for the MCP-1 
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chemokine and signaling through the CCR2/MCP-1 axis is required for the recruitment of 
inflammatory monocytes to the site of tissue damage. Targeting of monocytes with CCR2-
siRNA LNPs reduced the infiltration of inflammatory monocytes to the site of tissue injury 
in murine models of ischemia/reperfusion-induced myocardial infarction and reduced the 
size of atherosclerotic lesions in mice with established atherosclerosis. These LNPs also 
prolonged the survival of pancreatic islet grafts and reduced the size of lymphoma growth.57
Passive targeting of nanoparticles to phagocytic cells has also been used to reduce 
macrophage-mediated inflammation at sites of atherosclerotic plaques. Duivenvoorden et al. 
intravenously administered statin-loaded re-constituted high-density lipoprotein 
nanoparticles (S-rHDL NPs) and observed that they accumulated in the heart, aorta, spleen, 
liver and kidneys. More detailed analyses revealed that these S-rHDL NPs could accumulate 
in atherosclerotic lesions in an Apoe−/− mouse model of atherosclerosis. Vessel wall 
thickness and macrophage infiltration of plaques were decreased in groups that received S-
rHDL NPs compared to groups that received empty particles or unencapsulated statin. S-
rHDL NPs caused reduced viability and secretion of inflammatory cytokines from 
macrophages compared to empty rHDL particles in vitro. Statins have no effect on 
cholesterol levels in the Apoe−/− mouse model, and so their impact in these studies was 
ascribed to their anti-inflammatory effect on macrophages in atherosclerotic lesions.58
Active targeting through conjugation of ligands for cell-surface receptors can often increase 
the uptake of nanoparticles by phagocytic cells relative to non-targeted particles, and this 
has thus motivated exploration of this approach for delivery of immunoregulatory drugs to 
macrophages and monocytes. A number of receptors allow macrophage-specific targeting, 
including the Fc receptor, scavenger receptors and mannose receptors (MMR or CD206). 
Targeting the macrophage Fc receptor is achieved by coating nanoparticles with IgG, which 
accelerates uptake of particles and enhances their retention within macrophages.59 
Nanoparticles can also be targeted to the F4/80 receptor expressed on the macrophage 
surface. Laroui et al. designed anti-inflammatory therapeutic by encapsulating TNF-α 
siRNA in nanoparticles synthesized using poly(lactic acid)/PEG block co-polymers (PLA-
PEG NPs). PLA-PEG NPs were coated with anti-F4/80 antibody fragments and packaged 
into chitosan/alginate hydrogels. It is important to note that both empty and TNF-α siRNA 
encapsulated PLA-PEG NPs did not affect macrophage cell viability. Upon oral 
administration, these antibody-coated PLA-PEG NP-loaded hydrogels preferentially 
interacted with intestinal macrophages and attenuated the effects of dextran sodium sulphate 
mediated colitis.60
The macrophage mannose receptor (MMR) is expressed on mature macrophages and 
dendritic cells but not on monocytes in the blood circulation. Intratracheal delivery of 
mannosylated cationic liposomes has been used to specifically target alveolar 
macrophages.61 MMR expression is also increased on TAMs that are polarized toward the 
M2 phenotype.62 Locke et al. used mannosylated phospholipids to synthesize liposomes that 
encapsulated radionuclide64Cu to facilitate imaging of urethane-induced lung tumors. 
Fluorescently-labeled mannosylated liposomes (Man-Lipos) co-localized with lung tumors 
and had lower background signal than non-mannosylated liposomes demonstrating that 
Man-lipos can be used to specifically target TAMs and deliver cargoes to them (Fig. 4).63
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Single-walled carbon nanotubes (SWNTs) have also been used to target phagocytic cells 
trafficking to tumors. SWNTs coated with lipid-tailed poly(ethylene glycol) terminated by 
an integrin-targeting peptide RGD (arginine-glycine-aspartic acid) were shown to 
accumulate at tumor sites in mouse models of cancer.64 This was attributed to the 
preferential accumulation of SWNTs in tumors via the enhanced permeability retention 
(EPR) effect65 and the ability of the RGD peptide to bind to integrins expressed on tumor 
vasculature and on the surface of tumor cells.66 However, upon closer examination using 
intravital microscopy, Smith et al. showed that in addition to accumulating in the tumor due 
to EPR, 25% of intravenously injected SWNTs were taken up preferentially by Ly6Chi 
monocytes in the circulation, which were then recruited to the site of the tumor in response 
to inflammation. Conjugating RGD to SWNTs increased the recruitment of Ly6Chi 
monocytes into the tumor interstitium and resulted in increased accumulation of SWNTs at 
the tumor site.67 The mechanisms underlying preferential uptake of SWNTs by Ly6Chi 
monocytes are still unknown.
2.1.2 Neutrophils—Neutrophils are the “first responders” at sites of inflammation and 
play an important role in providing the initial defense against invading pathogens through 
phagocytosis of microbes and secretion of cytokines and reactive oxygen species.68 
However, prolonged neutrophil-mediated inflammation can lead to tissue damage and the 
pathogenesis of diseases such as arthritis, cancer and COPD.69 Targeting neutrophils in 
contexts where they mediate inflammation has been explored as a strategy to limit chronic 
inflammatory responses and minimize tissue damage. In many cases, completely inhibiting 
neutrophil entry into the site of tissue injury may also abrogate the beneficial aspect of the 
inflammatory response. Using nanomaterials to specifically control the delivery of agents 
that reduce neutrophil recruitment to different extents may be able to ameliorate an 
excessive inflammatory response without interfering with the beneficial role of 
inflammation. When neutrophils respond to inflammation-inducers like bacteria, they trans-
migrate through activated endothelial cells to reach the site of tissue injury or infection. 
Wang et al. synthesized denatured bovine serum albumin (BSA) nanoparticles that are 
specifically endocytosed by activated neutrophils that adhere to inflamed blood vessels. 
These nanoparticles were synthesized through a desolvation process using ethanol and 
stabilized through glutaraldehyde-induced cross-linking and could be loaded with drugs that 
modulate neutrophil function such as Syk inhibitors. Upon intravenous delivery, these 
particles reduced the accumulation of neutrophils adherent to activated lung endothelium in 
response to a systemic LPS injection.70 In a related strategy, polymer nanoparticles carrying 
the anti-inflammatory peptide Ac2-26 were targeted to sites of tissue injury by using 
collagen IV targeting peptides. Nanoparticles less than 100 nm in diameter were synthesized 
using biodegradable diblock poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) using the 
single-step nanoprecipitation self-assembly method. Encapsulation of Ac2-26 in these 
nanoparticles resulted in its increasing its half-life in circulation and preferentially targeting 
it to the site of tissue injury. Administering these particles intravenously resulted in a 30% 
reduction in neutrophil recruitment to the site of tissue injury in a hind-limb ischemia-
reperfusion injury murine model, which could help resolve the inflammatory response more 
quickly.71
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2.2 Targeting the Adaptive Immune System
The adaptive immune system comprises T-cells and B-cells. These cell types express a large 
diversity of clonal antigen receptors, permitting recognition of a wide repertoire of antigens 
expressed by foreign pathogens or cancer cells. Furthermore, cells of the adaptive immune 
system differentiate to become memory cells that ‘remember’ previous antigen exposures 
and launch a rapid immune response against previously encountered antigens. This property 
is known as immunologic memory, a hallmark of the adaptive immune system4.
2.2.1 T-cells—T-cells play a central role in the immune system’s ability to eliminate 
intracellular pathogens and tumors. Current cancer immunotherapies showing significant 
objective responses in the clinic such as treatment with checkpoint blockade antibodies or 
adoptive T-cell transfer are largely reliant on the ability of cytotoxic CD8+ T-cells to 
infiltrate tumors and destroy cancer cells, as are many other cancer immunotherapy 
strategies2. On the other hand, aberrant T-cell responses contribute to serious autoimmune 
diseases including Type 1 diabetes and multiple sclerosis.72 Thus, strategies to modulate the 
function of T-cells, either enhancing or suppressing their function, have been sought in a 
variety of disease settings. Depending on the therapeutic context, T-cells can be modified to 
carry cargo that either modify their own function or modulate the function of cells with 
which they interact.
Engineering T-cell function in cancer immunotherapy: Tumor-antigen specific T-cells 
that naturally arise in a patient (endogenous T-cells), expanded by a cancer vaccine, or 
artificially introduced by adoptive cell therapy can potentially attack and destroy cancer 
cells. However, strategies to expand these T-cells specifically in vivo or to block the 
immunosuppressive signals they face in the tumor microenvironment are of importance for 
maximizing the efficacy of immunotherapies. Nanoparticle delivery agents have been 
explored to address these issues and enhance the function of T-cell-based immunity in 
several ways.
One of the most promising clinical strategies for treating advanced melanoma and certain 
leukemias is via adoptive cell therapy (ACT).20,73 ACT involves transferring large numbers 
of autologous tumor-specific T-cells expanded ex vivo back into patients to mediate tumor 
regression. A key step in this treatment is the rapid expansion of antigen-specific T-cells in 
culture. Perica et al. designed artificial nano-APCs using dextran-coated iron oxide particles 
with surface coupled MHC-Ig dimers and anti-CD28 antibodies designed to allow magnetic 
field-based aggregation of particles bound to T-cell receptors (TCRs). Ex vivo stimulation of 
T-cells with these particles in the presence of a magnetic field enhanced TCR clustering, 
reduced the threshold of activation of T-cells and improved the efficacy of adoptive T-cell 
therapy (Fig. 5 A, B).74 A startup company, NexImmune, is working to develop this 
technology for adoptive T-cell therapy and other clinical applications.
A second approach to enhance ACT is to functionalize T-cells with nanoparticles that can 
influence their function in vivo. Following T-cell injection, patients receiving ACT are often 
treated with systemic adjuvant drugs like interleukin-2 (IL-2).75 In preclinical models a 
variety of supporting cytokines or immunomodulatory agents have been tested as systemic 
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supporting drugs that can promote continued expansion of the transferred T-cells in vivo, 
improve T-cell survival, enhance T-cell resistance to immunosuppression, or increase T-cell 
effector functions.76,77 However, cytokines like IL-2 and other immunomodulators often 
elicit severe toxicity when administered systemically, due to nonspecific lymphocyte 
activation in the circulation and pleiotropic effects on other cells.76,78 To better focus the 
influence of supporting drugs on the donor T-cells themselves, Stephan et al. engineered 
cytokine encapsulating multi-lamellar lipid nanoparticles and chemically conjugated them to 
T-cells ex vivo prior to adoptive transfer.79 Unexpectedly, linking nanoparticles to free thiols 
on T-cell surface proteins (Fig 5C) resulted in minimal particle internalization over several 
days in culture (Fig 5D). This enabled the nanocarriers to continuously release encapsulated 
cytokines for engineered autocrine stimulation of cell surface receptors. When T-cells were 
loaded with nanoparticle “backpacks” carrying stimulatory cytokines, this approach enabled 
80-fold increased T-cell expansion in vivo and significant enhancements in the efficacy of 
ACT, without toxicity (Fig. 5E).79 It was subsequently demonstrated that this cell surface 
conjugation strategy leads to coupling of particles to receptors known to be trafficked to the 
immune synapse formed at the contact between T-cells and tumor cells during tumor cell 
killing.80 Thus, as particle-decorated T-cells engaged tumor cells, the cell-bound 
nanoparticles were shown to be transported over the cell surface into the T-cell/tumor cell 
interface, enabling synapse-directed drug delivery.80
A third strategy is to use nanoparticles to deliver stimulatory or protective cues to T-cells 
directly in the tumor microenvironment. Kwong et al. designed immunostimulatory 
liposomes comprising PEGylated liposomes with surface-conjugated IL-2 and anti-CD137 
(a co-stimulatory receptor up-regulated on activated T-cells).81 These particles were 
designed to enable high doses of IL-2 and anti-CD137 to be injected into tumors and remain 
localized at the tumor site without systemic dissemination. This allowed local T-cell 
stimulation without systemic toxicity. Upon local intra-tumoral injection into established 
melanomas, this liposomal therapy resulted in improved ratios of tumor infiltrating CD8+ T-
cells to regulatory T-cells (T-regs), cured 70% of treated animals, and primed T-cells that 
traveled away from the injection site to suppress the growth of distal (untreated) tumors. 
Importantly, intratumoral injection of anti-CD137 and IL-2 anchored on liposomes allowed 
for non-toxic delivery of doses of anti-CD137 and IL-2 that would be lethal if administered 
systemically.26
Nanoparticles can also accumulate in tumors following systemic administration, due to the 
combination of leaky tumor vasculature and dysfunctional lymphatic clearance in many 
tumors (EPR effect).65 Park et al. designed a biodegradable hybrid core-shell delivery 
platform comprising nanoscale liposome-encapsulated polymer nanogels (nLgs). By 
incorporating a small molecule drug chelator (β-cyclodextrin) into the nanogel network, 
nLgs could encapsulate both a hydrophilic cytokine (IL-2) and a hydrophobic small 
molecule drug that inhibits the TGF-β receptor–I. TGF-β is one of the major negative 
regulatory signals produced in tumors,82 and these combination drug nLGs simultaneously 
provided cues to drive T-cell and NK-cell expansion while blocking a key 
immunosuppressive pathway. Systemic administration of these nLgs in melanoma tumor 
bearing mice resulted in curing 40% of the animals.82
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A final approach to target T-cells is to exploit the fact that lymphocytes continuously re-
circulate through the blood, and directly target these cells in the circulation. Zheng et al. 
synthesized PEGylated liposomes conjugated either to IL-2 or antibody fragments against an 
innocuous T-cell surface protein (Thy1) to target adoptively transferred T-cells in vivo.83 
When systemically administered, both IL-2 and anti-Thy1 targeted liposomes to adoptively 
transferred T-cells in vivo (Fig. 5F, G). The advantage of targeting a circulating cell type 
was evident in these data, as nearly 100% of the target cells were labeled following a single 
injection of liposomes. Notably, IL-2-liposomes were shown to stimulate greater ACT T-cell 
proliferation in vivo compared to equivalent soluble doses of the cytokine.83 An alternative 
to using antibodies or cytokines to target lymphocytes could be to use oligonucleotide 
aptamers.84 Recently, McNamara et al. reported the generation of aptamers that bind to the 
T-cell costimulatory receptor CD137 and are capable of binding to T-cells and delivering a 
stimulatory signal.85
Engineering T-cell function in autoimmunity: During αβ TCR rearrangement, throughout 
T-cell development, T-cells expressing TCRs that recognize self-proteins can be generated. 
Such autoreactive T-cells are not always completely eliminated before leaving the thymus, 
but are usually kept under control through multiple mechanisms of tolerance that act in the 
peripheral tissues.86 If these normal tolerance mechanisms fail, autoreactive T-cells can 
attack healthy tissues, giving rise to autoimmune diseases like multiple sclerosis, rheumatoid 
arthritis and type I diabetes.72 An ideal therapy for autoimmune disease would inhibit 
autoreactive immune cells without non-specifically diminishing the capacity of the immune 
system to respond to dangerous microbes. Nanoparticle therapeutics show promise for 
enabling such selective re-regulation of autoreactive T-cells.
Type I diabetes is caused by polyspecific CD8+ T-cells that recognize multiple epitopes 
expressed by pancreatic islet cells, and thus an antigen-specific therapeutic strategy would 
potentially require eliminating or tolerizing CD8+ T-cells with many different specificities. 
Tsai et al. discovered that stimulation of self-antigen specific CD8+ T-cells via iron oxide 
nanoparticles conjugated with autoantigen peptide-MHC complexes (pMHC-NPs) led to the 
expansion of a population of autoregulatory memory-like T-cells. These autoregulatory 
memory-like T-cells prevented the activation of autoreactive CD8+ T-cells through killing of 
APCs that present auto-antigens.87 The promotion of a suppressive/regulatory phenotype in 
these memory-like T-cells may be a result of TCR crosslinking by pMHC-NPs in the 
absence of the additional co-stimulatory signals T-cells would normally need to receive 
from dendritic cells for a productive activating immune response. Importantly, once 
expanded, pMHC-NP-induced autoregulatory T-cells could inhibit the activation of poly-
specific autoreactive CD8+ T-cell populations, thereby enabling establishment of normal 
glycemic levels in non-obese diabetic (NOD) mice.87
The identification of cell surface proteins uniquely expressed by autoreactive T-cells enables 
nanoparticle-based targeting strategies to directly modulate the function of these cells. For 
example, the Kv1.3 potassium channel, responsible for ion transport during T-cell 
activation,88 was identified as being expressed at elevated levels on autoreactive 
CD45RO+CCR7− T-effector memory cells (TEM) compared to non-autoreactive T-cells. 
Exploiting this finding, Hadju et al. designed liposomes encapsulating protamine sulfate 
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complexed with siRNA against the Kv1.3 channel, and targeted the liposomes via anti- 
CD45RO antibodies. These anti-CD45RO Kv1.3 siRNA-nanoparticles specifically bound to 
TEM cells in in vitro mixed cultures and resulted in reduced activation of TEM cells 
compared to anti-CD45RO scrambled-siRNA control nanoparticles. By specifically 
targeting Kv1.3 siRNA to TEM cells the influence of these NPs on other cell types 
expressing the Kv1.3 channel like neurons, adipose cells and macrophages is minimized. 
However, the efficacy of these targeted siRNA-carrying liposomes remains to be tested in 
vivo.89
Delivering cytotoxic drugs like doxorubicin specifically to autoreactive T-cells can result in 
their elimination. Fahmy et al. demonstrated this concept using PAMAM dendrimers 
encapsulating doxorubicin that were targeted to T-cells using antibodies or specific peptide-
MHC complexes.90 Similarly, delivering specific immunomodulators that influence the 
differentiation of T-cells can be used to manipulate T-cell development in vivo. CD4+ T-
cell-targeted PLGA particles encapsulating leukemia inhibitory factor (LIF) caused 
increased expression of FoxP3 and promoted CD4+ T-cell differentiation toward a 
regulatory lineage. These induced T-regs could induce peripheral tolerance and 
transplantation tolerance in vivo91.
Engineering T-cell function in infectious Disease: In HIV infection, CD4+ T-cells are a 
primary target of the virus. This has motivated a number of nanoparticle-based strategies to 
target therapeutic agents like anti-viral siRNA or antiretroviral drugs to CD4+ T-cells to 
block HIV replication. For example, lipid nanoparticles (LNPs) encapsulating anti-retroviral 
drug idinavir were targeted to CD4+ T-cells using peptides that recognize the CD4 co-
receptor. Pre-treatment of CD4+ T-cells with targeted LNPs resulted in reduced number of 
infected cells compared to non-targeted LNPs in vitro92. In another approach, highly 
branched carbosilane dendrimers were functionalized to deliver siRNA into CD4+ T-cells 
and macrophages (a second target of HIV infection).93 However, these delivery platforms 
need further testing in in vivo models of HIV infection. Promising in vivo data using 
dendrimers to deliver siRNA into astrocytes suggest that this platform could be used to treat 
HIV infections in vivo.94
2.2.2 B-cells—The vast majority of licensed vaccines protect through the induction of 
neutralizing antibody responses.9 Thus, the design of nanoparticles to enhance the 
engagement and activation of antigen-specific B-cells is of great relevance for vaccine 
development. Microbes are intrinsically biological particles (nanoparticles or 
microparticles), often displaying densely-arrayed repetitive copies of surface antigens 
involved in target cell binding; B-cells have evolved to recognize and respond to such 
structural features. Crosslinking of B-cell receptors by repetitively-arrayed antigen promotes 
signaling through the B-cell receptor: while binding of monovalent protein antigens can 
trigger partial signaling through BCRs,95 multimerized antigens trigger greater signaling, 
antigen internalization, and processing of antigen for presentation to CD4+ T-cells– a 
requirement for B-cells to receive T-cell help for antibody production.96,97 Generation of T-
dependent antigen-specific antibody responses has also been shown to require direct 
stimulation of Toll-like receptors (TLRs) in B cells.98,99 For T-independent antigens such as 
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bacterial polysaccharides (which cannot be presented to T-cells), early studies estimated that 
~20 repetitive epitopes with uniform spacing of ~12 nm were required to maximally 
stimulate antibody responses in vivo.100,101 Antigens displayed in rigid, closely spaced 
arrays on particles (as naturally present on many viruses) also stimulate extremely potent 
humoral responses to T-cell-dependent antigens. This is exemplified by the response to 
virus-like particles (VLPs), where self-assembled protein nanoparticles based on the capsids 
of viruses (e.g. hepatitis B, papilloma viruses) or bacteriophages (e.g. Qβ, MS2, AP205) 
trigger long-lived, high-avidity antibody responses following, in some cases, only a single 
injection.102–104 Indeed, this biology has motivated the use of recombinant VLPs as the 
basis of the licensed hepatitis B and human papilloma virus vaccines,105–107 and for many 
other vaccines currently in clinical trials.108 Even for aluminum salts, which are still the 
most widely used particulate adjuvants for human vaccines in the United States,109 vaccine 
efficacy has been directly linked to the strength of antigen binding to these inorganic 
particles.110 For example, for a recombinant smallpox L1-protein subunit vaccine, binding 
of antigen to alum particles was required for optimal immune responses.111 Phosphate 
buffer treatment, which changed the surface charge of the aluminum particulates from 
positive to negative prior to vaccination, disrupted protein binding and reduced serum IgG 
titers, leading to increased morbidity and weight loss (an indirect measure of disease state) 
upon vaccinia virus challenge.
The immune response to native microbes and vaccines described above has motivated the 
study of synthetic nanoparticles that incorporate similar structural features in antigen display 
to promote humoral immunity. Engineered nanoparticles offer flexibility over the mode of 
particulate antigen display (e.g. encapsulated, non-covalently surface displayed, surface 
tethered).112–114 Antigen encapsulation has widely been used to load large amounts of 
antigen into particle cores and also acts as a means to shield protein payloads from proteases 
and other denaturants prior to immune cell targeting. While some techniques have been 
employed to improve antigen loading, this approach generally suffers from poor control over 
the degree of encapsulation and varies widely based on the particle platform and antigen 
properties (i.e. hydrophobicity, size, charge). Alternatively, surface display of protein and 
peptide antigens on nanoparticle surfaces mimicking viral and bacterial pathogens can 
potentially bind to and activate antigen-specific B cells more readily than encapsulated 
antigens, which by definition must be released to interact with B-cells (Fig 6). This has been 
demonstrated unequivocally by Friede et al. by showing that liposomes with surface bound 
peptide antigens elicited a much stronger B-cell response compared to liposomes with 
encapsulated peptide antigens at equivalent doses.115 Furthermore, covalently conjugated 
protein on the surface of calcium phosphate nanoparticles promoted BCR crosslinking in 
vitro and was 100-fold more efficient in activating antigen-specific B cells compared to 
soluble protein.116 While surface display requires an additional conjugation step post-
particle formulation, this allows for higher control over the degree of coupling based on the 
conjugation chemistry and antigen of interest, as well as the use of particles made using 
harsh solvents. For particle surface-displayed antigens, many physicochemical factors are 
expected to influence the ability of nanoparticles to engage B-cells. For example, Stefanick 
et al. described how peptide valency, peptide linker length, peptide hydrophilicity, 
poly(ethylene glycol) (PEG) coating density, and PEG linker length can dramatically alter 
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cellular uptake for peptide-functionalized liposomes binding to target cells, highlighting the 
importance of each these design elements on effective particle binding and uptake.117,118
Lipid-coated PLGA nanoparticles with only 10 ng of surface-displayed ovalbumin (OVA), a 
commonly used model protein antigen, elicited detectable serum IgG titers in vivo after a 
single immunization and further elicited 1000-fold higher titers compared to soluble OVA 
combined with adjuvant 1-week post-boost immunization.119 Nanoparticle surface-
displayed antigen can also result in increased germinal center formation and, as a 
consequence, higher affinity antibodies compared to soluble antigen immunization.120 More 
recently, gold nanoparticle-conjugated glycoprotein antigens have shown efficacy in non-
human primate studies against glanders.121 While vaccination did not result in a survival 
benefit upon bacterial challenge, those animals that were vaccinated and survived had 
significantly higher LPS-specific IgG titers compared to those who did not survive.
3 Overcoming tissue barriers for vaccines and immunotherapies with 
nanoparticles
A key aspect to the design of effective vaccines and immunotherapies is the ability to 
overcome relevant tissue barriers and efficiently deliver the therapeutic payload to a 
particular tissue destination. The tissue barriers most often encountered in vaccine/
immunotherapeutic design are mucosal and epithelial sites, and the frequently-targeted 
tissue sites for vaccines and immunotherapies are lymph nodes and tumors. In vaccination, it 
is often desirable to specifically initiate immune responses at the lymph nodes draining 
mucosal portals of entry of the target pathogen, because T-cells and B-cells activated in 
these lymph nodes are programmed to home back to the local mucosal tissue.122,123 For 
example, to promote protection from a respiratory pathogen such as influenza, pulmonary 
vaccination (intranasal or airway delivery of vaccines) is of interest, because this route of 
administration primes T-cells that home to the lung where they can become resident memory 
cells to protect the airway mucosa.124 The unique and effective ways in which nanoparticles 
have been utilized to overcome tissue barriers and/or to enhance tissue delivery will be 
reviewed in this section. As will be appreciated from this discussion, some of the effective 
roles for nanoparticles in these applications are generic properties relevant for delivery of 
any drug across these barriers, and other aspects relate specifically to the interaction of 
nanoparticles with the immune system.
3.1 Targeting therapeutics and vaccines to lymph nodes
Lymph nodes are the sites of lymphocyte priming by antigen presenting cells (APCs) and 
subsequent adaptive immune responses including T-cell differentiation, formation of 
germinal centers (where B cells undergo affinity maturation), and ultimately, the generation 
of long-term immunological memory. Therefore, it is cogent to hypothesize that direct 
delivery of immunotherapeutics/vaccines to lymph nodes may be more effective than distal 
administration to peripheral tissues. Indeed, extensive work by Johansen and colleagues has 
demonstrated the value of vaccine delivery to lymph nodes; for example, direct 
intralymphatic immunization substantially increased the ability of the Baccillus Calmette-
Guérin (BCG) tuberculosis vaccine to generate BCG-specific CD8+ and CD4+ T cell 
Irvine et al. Page 15
Chem Rev. Author manuscript; available in PMC 2015 December 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
responses and sustained protection against tuberculosis challenge, whereas subcutaneous 
immunization with a 100-fold higher dose did not.125 Synthetic nanoparticles can further 
modulate the response to intranodal injections, and offer an alternative means to achieve 
lymph node targeting of vaccines and immunotherapies.
3.1.1 Intranodal administration of nanoparticles—The most straightforward method 
to deliver vaccines to a lymph node is to directly inject intranodally. Ultrasound-guided 
intranodal administration of immunotherapies has been used in multiple phase 1 clinical 
trials.126–129 Although this can be performed with soluble therapeutics, use of 
nanoparticulate antigen is advantageous because nanoparticles reduce the rate of vaccine/
drug clearance from the lymphoid tissue and facilitate antigen uptake by antigen presenting 
cells.130 For example, Jewell et al. reported that intranodal injection of the TLR-3 agonists 
poly(inosinic:cytidylic acid) (polyIC) in particulate form substantially prolonged persistence 
of polyIC in lymph nodes when compared to soluble polyIC.131 In an immunization model, 
intranodal injection of ovalbumin-loaded particles induced much stronger humoral and 
cellular immune responses than intranodal injection of soluble ovalbumin.131 In another 
study, the intranodal injection of nanoparticulate ovalbumin and CpG substantially enhanced 
the IgG2A antibody response over intranodal injection of soluble vaccine.132 Thus, even on 
direct administration to lymphoid tissues, nanoparticle formulations can alter and enhance 
the response to vaccines.
3.1.2 Size-based LN targeting—Although intranodal injection may be useful for 
immunotherapeutic applications, it is impractical for widespread prophylactic vaccination 
settings. An alternative is to deliver materials to lymph nodes through lymphatic drainage of 
interstitial fluid from peripheral tissue injection sites. The fate of soluble materials following 
parenteral injection is highly dependent on physical size; the blood absorbs ~10-fold more 
fluid from tissues than lymph, so molecules small enough to enter blood vessels 
predominately clear to the blood. In general, materials larger than approximately 9 nm in 
diameter preferentially drain to lymphatics, whereas molecules/particles smaller than ~6 nm 
drain to the blood (Fig. 7).133 Conversely, very large solid particles (greater than ~50–100 
nm) tend to become trapped in the extracellular matrix and cannot freely drain to 
lymphatics, but can be phagocytosed and transported to lymph nodes by DCs present in the 
tissue or monocytes that emigrate from the blood.134 Thus, nanoparticles of appropriate size 
can be efficient synthetic vehicles to deliver vaccines or immuontherapeutics to lymph 
nodes.
The optimum size of particles for lymph node targeting have been examined in a number of 
studies. Hubbell, Swartz, and colleagues compared the ability of 20–100 nm PEGylated 
poly(propylene sulfide) nanoparticles to drain to lymph nodes and to stimulate immune 
responses. Larger particles with mean diameters of 100 nm were only 10% as efficient as the 
smallest particles at draining to lymph nodes and 20–45 nm diam. particles subsequently 
induced the strongest immune responses.135,136 While smaller particles achieve more 
efficient diffusion through peripheral tissue to reach lymphatics, Kourtis et al. also 
demonstrated in the same system that a portion of very small particles (30 nm diam.) are not 
necessarily trapped in the draining lymph nodes, and can be detected at substantial 
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concentrations in the peripheral blood within ~12 hr following intradermal injection.137 This 
finding suggests that at least for these phagocytosis-resistant PEGylated materials, very 
small particles can pass through the lymph nodes without capture, reaching the thoracic duct 
(and thereby enter the blood). Using model monodisperse polystyrene particles of different 
sizes, Fifis et al.138,139 and Manolova et al.134, reached similar conclusions, finding that 
particles less than 50 nm in diameter were most effective in lymph node trafficking and 
targeting lymph node-resident dendritic cells. While these studies seem to suggest that 
particles of ~200 nm diam. or larger can only reach lymph nodes through cell-mediated 
transport or through hydrodynamic/swelling effects caused by the injections themselves, a 
recent study by Gerner et al. showed that 200 nm nanoparticles applied passively to 
disrupted ear skin of mice were rapidly trafficked to lymph nodes through lymph, 
independent of cellular uptake.140 Thus, the precise size limits for lymphatic targeting of 
solid particles likely depend on both the tissue site and route of administration. Importantly, 
nanoparticle aspect ratio has also been identified as a key parameter in influencing lymph 
node draining of solid nanoparticles. Utilizing a unique mold-based particle fabrication 
process termed PRINT (i.e. particle replication in nonwetting templates), Mueller et al. 
identified anionic 80×180 nm cylindrical particles as having higher levels of lymph node 
drainage and subsequent APC uptake compared to other rod-like and spherical particles.141
Size limits for efficient lymphatic uptake are also altered when flexible particles are studied, 
rather than rigid solid particles. For example, liposomes with surface-displayed peptide 
antigens as large as 150 – 200 nm show substantial lymph node uptake following s.c. 
injection in mice, and induced 15–20-fold stronger antibody responses than smaller 65 nm 
vesicles.142 Increasing liposome size has been associated with decreasing drainage from 
peripheral injection sites but increased trapping in lymph nodes.143 This competing interplay 
between injection site drainage and lymph node retention suggests there exists an optimum 
nanoparticle size, which may vary with material composition and should be determined for 
each nanoparticle delivery system– these size ranges are a useful rule of thumb, but 
lymphatic uptake will be further influenced by the surface chemistry of the particle, antigen 
dose and type, and immunization route.144,145
For vaccines, lymph node targeting of adjuvant compounds is equally if not more important 
than lymphatic uptake of antigen, because potent adjuvants that distribute into the blood or 
pass through lymph nodes to reach the systemic circulation can induce unacceptable 
systemic inflammatory toxicity. Nanoparticle targeting of adjuvants to lymph nodes can thus 
increase both efficacy and safety. For example, a study of 3M-052, an adjuvant molecule 
that binds to Toll-like receptor 7/8, demonstrated that loading of this compound in 
liposomes promoted dose-sparing of the adjuvant and avoidance of systemic 
inflammation.146 Similarly, Ilyinskii et al. demonstrated that s.c. administration of the 
TLR7/8 agonist resiquimod in soluble form elicited pronounced systemic inflammatory 
cytokines and no local cytokine induction in draining lymph nodes, while the same 
compound delivered in PEGylated PLGA nanoparticles elicited strong localized cytokine 
induction in draining lymph nodes but no systemic inflammatory toxicity.147 Similarly, 
nanoparticle formulation is being explored as a method to enhance the lymph node drainage 
and retention of antiretroviral drugs, and lipid complexes were reported to efficiently deliver 
the antiretroviral drug indinavir to lymph nodes after subcutaneous injection.148,149
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3.1.3 Promoting vaccine/therapeutic capture in lymph nodes—On reaching 
lymph nodes through the lymphatics, nanoparticles are often either captured by 
macrophages or dendritic cells lining the subcapsular sinus or medullary sinuses of the 
lymph node.150–152 In some cases, nanoparticles have been shown to accumulate and persist 
in lymph nodes for extended periods, which may contribute to enhanced immune responses 
to particulate vaccines.153 Recently, several groups have expanded upon the size-based 
targeting strategy of nanoparticles to also incorporate specific ligands to promote vaccine 
particle capture by specific cell types in lymph nodes. Inclusion of mannose on the surface 
of PEGylated liposomes containing encapsulated antigen enhanced the binding to and 
uptake into APCs that express the mannose receptor. Subsequently, mannose nanoparticles 
generated stronger humoral immune responses than unlabeled nanoparticles.154 The cell 
surface receptors CD40, DEC-205 and CD11c expressed by dendritic cells have also been 
targeted for enhanced lymph node delivery. PLGA nanoparticles conjugated with antibodies 
against each of these molecules all exhibited enhanced dendritic cell uptake and T-cell 
stimulatory capacity in vitro in comparison to untargeted nanoparticles.155 In a subsequent 
study, the presence of anti-CD40 on nanoparticles (NP-CD40) improved dendritic cell 
uptake of antigen in draining lymph nodes after subcutaneous administration in mice and 
modestly improved both therapeutic and prophylactic treatment efficacies in a tumor model 
(Fig. 8).156 Larger doses of co-delivered TLR agonists – which were shown to be essential 
for DC maturation after nanoparticulate antigen uptake – will likely further enhance these 
immune responses. The composition of the nanoparticle itself can also influence particle 
uptake in lymphoid tissues. For example, cholesteryl pullulan nanogels were shown to be 
selectively engulfed by medullary macrophages in draining lymph nodes after subcutaneous 
injection.157 In comparison to soluble antigen formulated in Incomplete Freund’s Adjuvant, 
antigen encapsulated in these hydrogel nanoparticles substantially delayed tumor growth in a 
cancer therapeutic model.157
3.2 Nanoparticles to penetrate mucosal and epithelial barriers for vaccines and 
immunomodulation
Most current human vaccines are administered parenterally, resulting in strong systemic 
immune responses and weak to non-existent mucosal immune responses. Yet most 
pathogens infect through mucosal tissues,158,159 and the establishment of mucosa-homing T-
cells and B-cells through mucosal immunization can be a key component of vaccine 
efficacy.160–162 The inductive sites of the mucosal immune system consist of both mucosa-
associated lymphoid tissues (MALT) and mucosa-draining lymph nodes, and include the 
tonsils in the upper respiratory airway and Peyer’s patches in the intestines. Although the 
composition and structure of mucosal tissue varies depending on location (oral/intestinal 
tract, nasal/respiratory tract, genital tract), it can generally be classified as either type I or 
type II mucosal tissue. Gut-associated lymphoid tissue (GALT), nasal-associated lymphoid 
tissue, and uterine mucosal tissue of the female genital tract (FGT) are all type I mucosal 
tissue, while vaginal mucosal tissue is type II.163 Type I mucosae consists of simple 
columnar epithelium linked by tight gap junctions while type II mucosae is lined with 
multilayer stratified squamous epithelium.164 IgA in the main predominant immunoglobulin 
produced in type I mucosal tissues, but IgG is the primary immunoglobulin of type II 
mucosal tissues.
Irvine et al. Page 18
Chem Rev. Author manuscript; available in PMC 2015 December 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
For vaccines, local administration initiates immune responses concentrated at the mucosal 
site, but mucosal vaccine development is complicated by the same safety vs. efficacy 
considerations of parenteral vaccines. Furthermore, delivery of a vaccine to the inductive 
sites of the mucosal immune system (draining lymph nodes and MALT), requires mucus 
penetration, crossing the epithelial barrier, and eventual drainage to local lymph nodes. 
Nanoparticles are attractive mucosal vaccine/immunotherapy delivery vehicles due to the 
enhanced uptake by APCs of particulate antigen, the preferential draining of nanoparticles to 
lymphatics rather than to the blood stream (as discussed in the previous section), and lastly, 
depending on size and composition, the ability of nanoparticles to diffuse through mucus 
and cross mucosal barriers.
3.2.1 Airways and nasal mucosa—Intranasal administration is needle free and 
noninvasive, and allows access to the rich immunological environment of the respiratory 
mucosa. The epithelium of the airways and nasal mucosa contain Microfold cells (M-cells), 
which transcytose particulate matter across the epithelial layer to underlying lymphoid 
follicles of the MALT.165 The first studies to suggest a potent role for nanoparticles in 
pulmonary vaccines were published in the late 1990s. An early HIV vaccine study 
demonstrated that a gp160 DNA-based intranasal vaccine induced stronger serum and 
mucosal antibody titers than the equivalent intramuscular vaccine. Furthermore, co-
administration with cationic liposomes—to which the negatively charged DNA antigen will 
bind—adjuvanted both humoral and cell-mediated vaccine-specific immune activity.166 
Two years later, Klavinskis et al. reported that after intranasal administration of plasmid 
DNA-lipid nanocomplexes, DNA was distributed in the respiratory tract, draining lymph 
nodes and spleen. This nanoparticulate DNA vaccine induced serum and mucosal antibodies 
significantly superior to those produced by unformulated DNA.167
Several strategies have been pursued to further develop strategies for effective pulmonary 
vaccine/immunotherapy treatment using nanoparticles. An anatomic approach is to deliver 
nanoparticles to the deep lung, targeting the large population of dendritic cells lining the 
alveoli (air sacs of the lung), which actively extend processes into the alveolar lumen to 
survey for microbes.168 Using crosslink-stabilized lipid nanocapsules loaded with antigen 
and TLR agonist adjuvants, Li et al. demonstrated that nanocapsules (ICMVs) were captured 
much more efficiently than soluble vaccines by APCs in the lungs following pulmonary 
instillation (mimicking aerosol administration).169 This led to greatly increased and 
prolonged antigen presentation in lung-draining lymph nodes, and transformed an antigen/
adjuvant combination that was completely non-protective against a viral challenge as a 
soluble formulation to a 100% protective vaccine (Fig. 9). In another example, Vicente et al. 
developed lipid-chitosan hybrid nanoparticles consisting of an oily core loaded with 
imiquimod and surrounded by a phospholipid layer and a chitosan coating onto which a 
hepatitis B protein antigen was adsorbed. These nanoparticles were taken up by 
macrophages and generated long-lived antigen-specific antibody titers.170 Consistent with 
the idea that nanoparticle capture by APCs is particularly efficient in the deep respiratory 
tract, Sanders et al. demonstrated that antigen formulated with ISCOMATRIX nanoparticles 
(lipid vesicles consisting of phospholipid, cholesterol and saponin) induced much stronger 
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immune responses when delivered to the total respiratory tract rather than only the upper 
respiratory airways.171
A second strategy that has shown promise for enhancing vaccine uptake by immune cells at 
pulmonary mucosal surfaces has been to employ nanoparticles that are mucoadhesive, to 
increase the particles’ residence time at the epithelial surface. Using cationic cholesteryl 
pullulan nanogels (cCHPs) as vaccine carriers, Nochi et al. demonstrated increased retention 
in the nasal mucosa and uptake of antigen by mucosal dendritic cells (Fig. 10). This 
enhanced antigen delivery translated to significantly increased mucosal antibody responses 
and protection from Clostridium botulinum challenge.172
An orthogonal approach is to design nanoparticle carriers to efficiently diffuse through 
mucus and reach the underlying epithelium, where capture by APCs or transcytosis by 
epithelial cells could provide effective uptake of vaccines/immunomodulators. A dense 
surface coating of poly(ethylene glycol) on nanoparticles has been reported by the Hanes 
and Saltzman groups to enhance the mucus-penetrating abilities of nanoparticles.173,174 
Though not explicitly tested for mucus-penetration efficiency, vaccines prepared by the 
Hubbell and Swartz labs using PEGylated poly(propylene sulfide) nanoparticles (PPS-NPs) 
surface-conjugated with protein antigen/molecular adjuvants may gain at least some of their 
efficacy from fulfilling these design criteria for effective mucus penetration. Intranasal 
administration of 50 nm PPS-NPs resulted in the deposition of particles in the nasal tissue, 
enhanced CD8+ T-cell responses in the lung and spleen, and enhanced mucosal antibody 
production in comparison to soluble antigen.175 The co-conjugation of the danger signal 
flagellin to PPS-NPs also increased antibody titers to the vaccine antigen. Furthermore, 30 
nm PPS-NPs loaded with ovalbumin, mixed with CpG, and administered via pulmonary 
delivery induced significantly enhanced cytotoxic CD8+ T-cell responses, providing 
enhanced protection against an influenza virus challenge compared to soluble pulmonary 
vaccine.176 Interestingly, in contrast to results obtained for peripheral lymph node targeting 
following parenteral injection, a comparison of intranasal administration of large (200 nm) 
vs. small (30 nm) PPS-NPs conjugated to the model antigen ovalbumin revealed that 200 nm 
PPS-NPs more effectively delivered ovalbumin to MHC class I and MHC class II antigen 
presentation pathways of APCs, enhanced lung CD4+ T-cell responses, and increased 
systemic and mucosal antibody titers compared to 30 nm PPS-NPs.177 These results suggest 
that cell-mediated transport of particulate antigens to lymph nodes may be particularly 
important or more efficient for mucosal immune responses compared to direct lymph node 
targeting at these barrier sites.
In addition to mucus penetration, nanoparticles have also been designed to promote binding 
to epithelial cells and transport across the epithelial barrier to enhance pulmonary vaccine 
responses. Heparin-binding hemagglutinin adhesion (HBHA) protein is known to bind to 
heparin-sulfate-containing receptors on lung epithelial cells. Antigen-HBHA constructs 
adsorbed onto the surface of wax nanoparticles induced stronger humoral and cellular 
immune responses after intranasal administration than antigen-only nanoparticles or soluble 
antigen-HBHA protein fusions.178
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Nanoparticle vehicles have also been designed to more actively promote transit across the 
epithelial barrier at mucosal surfaces. Chitosan is a biocompatible cationic polysaccharide 
that is mucoadhesive and capable of reversibly opening epithelial tight gap junctions.179 
Following the demonstration of enhanced systemic uptake of insulin when intranasally 
administered in chitosan nanoparticles180, there has been considerable interest in the 
development of chitosan nanoparticles as pulmonary delivery vehicles for a wide range of 
applications. Intranasal administration of chitosan-DNA nanoparticles expressing the 
streptococcus pneumonia surface antigen A generated stronger mucosal and systemic 
antibody titers than naked DNA.181 Encapsulated influenza protein antigen in chitosan 
nanoparticles was shown to induce stronger mucosal and systemic anti-vaccine antibody 
titers than soluble antigen alone. Furthermore, chitosan nanoparticles conferred 100% 
protection against lethal intranasal influenza challenge.182 Bal et al. undertook a 
comprehensive study of the humoral effects of immunomodulators when co-encapsulated 
with antigen in chitosan nanoparticles in intranasal or intradermal vaccination models. As 
expected, nanoparticulate antigen induced stronger antibody responses regardless of 
immunization route, but the potency of immunomodulators—CpG, lipopolysaccharide, 
PAM3CSK4, muramyldipeptide, and cholera toxin subunit B—was dependent on the 
immunization route.183 These results likely reflect different APC populations residing in 
different tissues, and highlight the necessity of matching optimal immunomodulators to the 
immunization route in vaccine and immunotherapy development.
In addition to chitosan, PPS, and lipid nanoparticles, several other nanoparticle formulations 
are currently in development as pulmonary vaccine delivery systems. Silica particles taken 
up by APCs can activate an intracellular inflammatory signaling pathway known as the 
inflammasome.184,185 Exploiting this intrinsic adjuvant property of silica particles, 
intratracheal administration of soluble influenza protein antigen co-formulated with silica 
nanoparticles generated stronger mucosal antibody responses but weaker systemic antibody 
responses than intraperitoneal administration of influenza protein formulated in alum.186 In 
an interesting example of long-term antigen release, polyanhydride nanoparticles with 
encapsulated antigen were designed to release antigen over a 28 day period.187 When 
immunized via intranasal administration, mice receiving antigen-loaded nanoparticles 
produced sustained titers of high avidity antibodies and were protected against Yersinia 
pestis challenge.
A critical consideration for pulmonary vaccine administration is the potential for the 
induction of dangerous airway inflammation or fibrotic responses. By targeting phagocytic 
dendritic cells, nanoparticles may help to ensure that only danger sensor receptors on innate 
cells critical to induction of the desired immune response are stimulated and avoid triggering 
lung epithelial cells themselves. Importantly, a recent study comparing the surface 
hydrophobicity of nanoparticles and the resulting histopathology after intratracheal 
administration demonstrated that hydrophobic nanoparticles were not biocompatible while 
hydrophilic nanoparticles (coated with PEG or lecithin) were well tolerated in lung tissue.188 
Hydrophilic nanoparticles have also been shown to have increased plasma bioavailability 
after oral or intranasal administration, suggesting hydrophilicity is a key component for 
antigen transport across mucosal barriers.189,190
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3.2.2 Gastrointestinal tract—The oral delivery route offers a multitude of advantages 
for vaccines and immunotherapy treatment: it dispenses with risks from needle use (or re-
use); is amenable to self-administration with high patience compliance; and for vaccines, 
leads to the induction of both systemic and mucosal immunity. However, oral 
immunomodulators must first survive exposure to the stomach pH, proteolytic enzymes and 
bile salts in the gastrointestinal (GI) tract, and then transit through mucus and the gut 
epithelium to reach the gut-associated lymphoid tissue (GALT). Nanoparticles offer 
opportunities to both protect vaccines/immunotherapeutics from degradation, and effectively 
transport particles across the intestinal lumen. With respect to degradation protection, 
encapsulation of antigen inside polymeric nanoparticles has been the predominant approach. 
Understanding the stability of any given antigen/nanoparticle system when exposed to 
gastric and intestinal fluid should be a key component in the design of a novel oral 
vaccine.191 As this chapter is centered upon the use of nanoparticles to overcome tissue 
barriers, the rest of this section will focus on methods currently in development to use 
nanoparticles as intestinal lumen transporters.
In 1997, Desai et al. first observed that 100 nm PLGA nanoparticles were taken up by 
intestinal tissues much more efficiently than soluble coumarin-6 dye or 500 nm – 5 µm 
particles.192 This size-dependent uptake suggested that nanoparticles may be efficacious 
delivery vehicles for materials that are not readily absorbed in the intestinal tract, and 
subsequent particulate delivery systems have primarily utilized nanoparticles in the 100 – 
500 nm diam. range. For example, oral administration of 470 nm mesoporous carbon 
nanoparticles (C1) loaded with antigen induced serum antibody responses nearly equivalent 
to intramuscular administration of antigen emulsified in Complete Freund’s Adjuvant, a 
gold-standard experimental adjuvant that is too toxic for human use (Fig. 11).193 On the 
other end of the size spectrum, chitosan-functionalized gold nanoparticles have also been 
investigated as potential oral vaccine delivery systems. Chitosan nanoparticles 20–40 nm in 
diam. with surface-adsorbed antigen generated stronger titers than soluble antigen following 
oral immunization, and the co-adsorption of saponin-containing adjuvants further enhanced 
humoral responses elicited by these particles.194,195
An important mechanism for particle uptake from the gut lumen into the GALT is proposed 
to be via microfold cells (M-cells), a specialized epithelial cell that overlies lymphoid tissue 
structures of the small intestine known as Peyer’s patches. M-cells efficiently internalize and 
transcytose particulate antigens across the gut epithelium into basolateral pockets where 
antigen presenting cells reside, thereby playing a key role in initiating adaptive immune 
responses in the gut.196 Targeting M-cells has been a major focus of oral vaccine 
development. Various lectins which bind specifically to M-cells have been investigated for 
use as M-cell targeted vaccines, and both lectin-coated PLGA particles and liposomes have 
been shown to enhance uptake of encapsulated antigen into M-cells and induce stronger 
humoral immune responses following oral delivery than unmodified particles.197,198 In an 
alternative approach, PLGA nanoparticles have been functionalized with RGD analogs in 
order to target β1 integrins on the apical surface of M-cells; this functionalization enhanced 
nanoparticle uptake and humoral immune responses after intraduodenal administration.199 
Slütter et al. demonstrated that N-trimethylated chitosan nanoparticles enhanced antigen 
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transport in an M-cell dependent manner and promoted dendritic cell activation in vitro, 
although this did not impact the humoral response in vivo after intraduodenal 
administration.200 One significant disadvantage of chitosan nanoparticles is that chitosan 
rapidly dissolves at pH 1.2 – 2.0 and thus chitosan NPs would be expected to dissolve in the 
stomach.201 One solution to this challenge reported by Jain et al. was to encapsulate antigen-
loaded chitosan nanoparticles within liposome- or niosome-microparticles to protect the NPs 
during transit through the stomach.202 In comparison to “naked” chitosan NPs, encapsulated 
particles efficiently retained antigen when exposed to simulated gastric fluid (pH 1.2) and 
induced significantly higher serum IgG titers after oral immunization. An alternative method 
to stabilize chitosan nanoparticles is to crosslink the chitosan polymers. Harde et al. 
developed a method to tandem crosslink chitosan nanoparticles using tripolyphosphate 
followed by glutaraldehyde.203 These crosslinked chitosan nanoparticles exhibited greater 
stability in acidic environments, enhanced uptake by antigen-presenting cells, greater 
intestinal permeation, and significantly stronger systemic and mucosal antibody responses 
than unmodified chitosan nanoparticles after oral administration.203
M-cells are particularly attractive targets for nanoparticle delivery because of their specific 
localization over gut lymphoid tissues, but this also means that these cells make up a 
relatively small portion of the total gut epithelium. Thus, other routes for receptor-specific 
uptake of have also been explored, targeting receptors expressed on normal gut epithelial 
cells: Thiamine – a member of the vitamin B family – is absorbed from the intestinal lumen 
in a specialized, carrier-dependent mechanism.204 Thiamine-coated poly(methyl vinyl ether-
co-maleic anhydride) nanoparticles have been shown to adhere to gut mucosa in a thiamine 
dependent manner and when administered orally, thiamine-coated nanoparticles induced 
substantially stronger humoral responses than plain nanoparticles.205
The co-delivery of TLR-4 or TLR-2 agonists may also be an effective method to enhance 
transport across the intestinal lumen. TLR-4 agonism has been reported to increase intestinal 
epithelial tight junction permeability206 and administration of lipopolysaccharide, a TLR-4 
ligand, enhanced intestinal adsorption of microparticles.207 In addition, TLR-2 agonism has 
shown to enhance the transcytosis of microparticles by M-cells in a dose-dependent 
manner207 as well as induce the migration of dendritic cells into the follicle-associated 
epithelium of the GALT.208 These observations suggest TLR-4 and TLR-2-based adjuvants 
may play a role in the intestinal fate of nanoparticulate vaccines and should be taken into 
account when designing future oral vaccines. Conventional wisdom has held that 
mucoadhesive nanoparticles will enhance the intestinal adsorption of nanoparticles, however 
recent studies are challenging this assumption. Maisel et al. demonstrated that PEGylation of 
polystyrene nanoparticles eliminated the mucoadhesiveness of polystyrene nanoparticles and 
enabled widespread nanoparticle penetration of the intestinal tract in both healthy and 
ulcerative colitis mouse models.173 PEGylation has also been demonstrated to enhance the 
intestinal tract permeation of solid lipid nanoparticles (SLNs), as shown in Fig. 12.209 
Whether or not this enhanced intestinal adsorption of antigen via hydrophilic, mucus 
penetrating particles enhances immune responses remains to be seen.
Efficient delivery to the lower gastrointestinal tract without pH-dependent or enzymatic 
degradation of antigen in the proximal gut still remains a critical hurdle in the development 
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of an oral vaccine. To target the large intestine, Zhu et al. coated PLGA nanoparticles with 
an anionic copolymer (Eudragit FS30D) that is soluble only at pH > 7.0, a pH only present 
in the terminal ileum.210 Particles were taken up in the large intestine and not the small 
intestine, and oral administration of antigen-loaded particles induced stronger mucosal 
immune responses than intra-colorectal administration of soluble antigen.210 This two-stage 
delivery approach demonstrates that pH-dependent release of nanoparticles within targeted 
regions of the GI tract may be an effective method to control the location of antigen delivery 
within the digestive system for future oral nanoparticulate vaccines.
3.2.3 Reproductive tract—The female genital tract (FGT) possesses several distinctive 
characteristics that require thoughtful design of FGT-targeted vaccines/immunotherapy. 
Importantly, the mucosal surface of the lower FGT tract (vagina) consists of a loosely-
connected multilayer squamous epithelium, while the mucosal surface of the upper FGT 
tract (uterus, cervix, and fallopian tubes) is a single layer of pseudo-squamous and simple 
columnar epithelia.211 These columnar epithelial cells of the upper FGT form tight junctions 
to maintain the integrity of the mucosal monolayer.212 The FGT lacks an equivalent of the 
M-cells present in the intestinal and nasal tracts. FGT epithelial cells act as both a physical 
barrier from the external environment and as innate immune sentinels; both uterine and 
vaginal epithelial cells express Toll-like receptors 1–9 and beta-defensins 1, 2, and 4.213 
Activation of TLRs on FGT epithelial cells induces the secretion of the chemoattractant 
CCL-2, which in turn recruits immune cells into the FGT and initiates an inflammatory 
response. Furthermore, FGT epithelial cells are non-professional APCs, capable of 
presenting antigen to CD4+ T-cells.214 Beneath the mucosal surface, the lamina propria of 
the FGT contains a cadre of immune cells including CD4+ and CD8+ T cells, B cells, plasma 
cells, DCs, macrophages, Langerhans cells (vagina), NK cells (uterus) and regulatory T-cells 
(uterus).215 Upon infection, Langerhans cells and DCs recognize pathogens, mature, and 
migrate to draining lymph nodes to prime naïve B and T cells.122 There are three significant 
barriers to effective vaginal delivery of immunotherapies: penetrating mucus, crossing the 
epithelial layer, and subsequently trafficking to the draining lymph node. As the suitability 
of nanoparticles to enable efficient lymph node delivery has already been discussed, this 
section will briefly discuss the development of mucus-penetrating particles and epithelial 
crossing particles for FGT-targeted therapies.
Mucus-penetrating particles possess hydrophilic surface-coatings that minimize interactions 
with mucus. The polymer PEG has alternatively been reported to be mucoadhesive or to be 
mucus-penetrating.216,217 To reconcile these observations, a study by Wang et. al. 
demonstrated that low molecular weight PEG at high surface-coating densities penetrates 
cervical-vaginal mucus (CVM) but high molecular weight PEG adheres to CVM in vitro.218 
Further in vivo studies compared conventional polystyrene nanoparticles (CPs) to CPs with a 
high density coating of low molecular weight PEG to be mucus-penentrating particles 
(MPPS) and revealed that MPPs were uniformly distributed across the murine vaginal 
epithelium while CPs were aggregated in vaginal mucus.219 Furthermore, MPPs were 
retained in the cervicovaginal tract whereas CPs were almost entirely flushed out in 6 hours, 
as shown in Fig. 13.219 Additional studies demonstrated that delivery of MPPs in hypotonic 
solution rather than isotonic solution further enhanced vaginal distribution and retention of 
Irvine et al. Page 24
Chem Rev. Author manuscript; available in PMC 2015 December 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the particles.220 MPPs loaded with the chemotherapeutic drug paclitaxel was demonstrated 
to control orthotopic TC-1 cervical tumor growth better and prolong mouse survival 
compared to paclitaxel-loaded CPs or Taxol (the clinical formulation of paclitaxel). PLGA 
nanoparticles have also been shown to penetrate CVM when coated with PEG174 and to 
induce long-lived systemic and local humoral immune responses after intravaginal 
administration221; these results suggest that MPPs could be effective delivery vehicles for 
vaginal vaccines.
3.3 Nanoparticle delivery in the skin
Transcutaneous immunization – vaccination through the skin—is an attractive alternative to 
needle-based immunizations due to its simplicity and potential for pain-free administration. 
The epidermis is a rich immunological site containing large numbers of epidermal 
Langerhans cells (skin-resident dendritic cells) that capture antigen and then migrate to 
draining lymph nodes to initiate adaptive immune responses222. A study of amorphous silica 
nanoparticles demonstrated that uptake by Langerhans cells in the skin was positively 
correlated with nanoparticle size, with 200 nm diameter nanoparticles exhibiting the most 
efficient uptake.223 In keeping with this observation, elastic liposomes designed to be 
capable of permeating through skin induced stronger systemic and salivary antibody 
responses than soluble antigen224 or antigen-loaded chitosan nanoparticles when applied 
topically to the skin, and modestly enhanced anti-tumor immunity.225 Mittal et al. induced 
strong cellular and humoral immune responses when a cyclic dinucleotide adjuvant – cyclic-
di-AMP – was included with antigen-loaded chitosan-PLGA nanoparticles and administered 
transcutaneously.226
Permeation of the hydrophobic stratum corneum to reach the epidermis is a considerable 
barrier to effective transcutaneous immunization. Protein transduction domains (PTDs) are 
commonly used as a skin permeation enhancer for macromolecules. Kitaoka et al. 
demonstrated that inclusion of the PTD polyarginine (R6) in a solid-in-oil nanodispersion 
(S/O) antigen delivery system generated higher systemic antibody responses than 
polyarginine-free nanodispersions or soluble antigen and polyarginine (Fig. 14).227
4 Modulating antigen presenting cells and innate immunity
Antigen presenting cells play a crucial role in the response to vaccines and 
immunotherapies, whether the goal is to promote immunity or tolerance. Among APCs, 
dendritic cells are particularly important for the primary immune response because they 
govern the activation of CD4+ and CD8+ T-cells, which provide help for antibody responses 
and exert direct cytotoxic activity on infected/transformed cells, respectively (Fig. 15).6,228 
Adjuvants incorporated into vaccines are often designed to act specifically on DCs, as 
regulation of DC activation determines the outcome of vaccination. Thus, a final key 
application of synthetic nanoparticles in immune engineering is modulation of APC 
function. Nanoparticles can act on APCs in several distinct ways, by encapsulating or 
displaying danger signals that promote DC activation, by triggering particle-specific 
immune recognition and antigen processing, delivering danger signals, or via intrinsic 
immunomodulatory effects on APCs. By “programming” the activation state of DCs or other 
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APCs, nanoparticle formulations directly impact the induction of cellular and humoral 
immunity to vaccines and immunotherapies.
4.1 Nanoparticulate antigen delivery to DCs to promote T-cell immunity
4.1.1 Enhancing antigen presentation to CD4+ T-cells—CD4+ T-cells are also 
known as helper T-cells since they provide required signals to B-cells to promote class 
switching and affinity maturation of the antibody response, instruct dendritic cells to 
maximize the induction of memory cells during CD8+ T-cell activation, and provide 
cytokines to instruct macrophages and other innate immune cells to clear infections. 
Dendritic cells serve as a gatekeeper on all of these processes, as they present peptide 
antigens bound to class II MHC molecules on their surfaces that activate CD4+ T-cells to 
carry out all of these functions. A role for nanoparticle carriers in promoting antigen 
delivery to APCs for CD4+ T-cell priming was first shown in the early 1990s, when it was 
demonstrated that nanoparticles (liposomes) carrying antigen designed to be stable on 
internalization by APCs until they reached acidic intracellular lysosomal compartments 
could promote antigen processing and presentation to CD4+ T-cells.229 Since then it has 
been shown that particle size and composition influence the capacity of nanoparticles to 
promote antigen delivery to class II MHC loading pathways.230 For example, OVA 
conjugated to 200 nm particles resulted in increased class I and II MHC presentation, CD4+ 
T cell responses in the lungs, systemic and musical immunity and, importantly, a higher 
percentage of antigen-specific polyfunctional CD4+ T cells compared to OVA conjugated to 
30 nm particles.177 For liposomes, lipid bilayer composition has been shown to dictate 
dendritic cell interactions- cationic liposomes containing antigen are readily internalized, 
while anionic liposome internalization can be improved upon addition of DC targeting 
moieties such as mannosylated phosphotidylserine.231 Taking advantage of their propensity 
for internalization into various cell types and large surface area available for chemical 
modification, single-walled carbon nanotubes have recently been utilized as novel vaccine 
carriers.232 Mice immunized with 50–400 nm peptide-conjugated carbon nanotubes along 
with a water-in-oil emulsion adjuvant induced peptide-specific IgG responses that were not 
present following immunization with the peptide and adjuvant alone.232
Nanoparticles also enable compartmentalization of the epitopes targeted by B-cell and 
helper T-cell responses. Minimal B-cell epitopes (e.g., short peptides) are of interest for 
eliciting highly focused antibody responses against a chosen target antigen. However, these 
short peptides may not be recognized by T-cells, and thus separate peptide antigens (helper 
epitopes) may need to be co-delivered to APCs to prime helper T-cell responses to such 
vaccines. Traditionally such B cell antigens are conjugated to carrier proteins capable of 
eliciting strong T-cell responses, such as diphtheria toxoid233 or keyhole limpet hemocyanin 
(KLH),234 or more recently linked directly to small T-cell help peptides.235 However, 
several disadvantages exist with these methods, including competing antibody responses to 
the carrier protein itself, antibodies developed to the conjugation site or irrelevant antibodies 
towards improperly oriented antigens, and limited conjugation sites for antigen loading and 
multivalency.236 This problem can be solved by a strategy know as “instructural help”: 
antigens encapsulated within nanoparticles are inaccessible to B-cells until released, but 
upon release from particles following internalization by B-cells or dendritic cells are readily 
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processed for loading onto MHC molecules for presentation to T-cells. Thus, particles 
encapsulating helper T-cell antigens but surface-displaying B-cell epitopes can be used to 
foster a B-cell response that is focused on the desired B-cell antigen without competition 
from B-cells recognizing the helper epitope. This has been demonstrated in the case of lipid 
nanoparticle vaccines displaying surface-bound peptides derived from the gp41 envelope 
protein of HIV (as a B-cell target), but containing encapsulated T-helper epitope peptides 
(Fig. 16).142 Encapsulation of the helper epitopes permitted efficient T-cell help to be 
provided in the vaccine while limiting the antibody response raised against the encapsulated 
T-cell peptides; by contrast strong humoral responses were elicited against the surface-
displayed gp41 peptide.142
4.1.2 Particulate delivery for cross presentation of protein antigens—For most 
prophylactic vaccines success is measured by the ability to produce long-lasting antibody 
responses to block infection. However, for some viruses like HIV, intracellular pathogens, 
and cancer, CD8+ T-cell responses are required to act synergistically with humoral 
immunity to eliminate infected cells or destroy tumors. This presents a challenge as typically 
only live infections elicit strong CD8+ T-cell priming. Soluble antigens acquired by DCs 
from the extracellular environment are internalized into endolysosomal compartments, 
broken down into peptides, and loaded almost exclusively onto class II MHC molecules for 
presentation to CD4+ helper T-cells. By contrast, class I MHC molecules that present 
peptides to CD8+ killer T-cells are usually only loaded with antigens located in the cytosol 
of DCs.237 Because cytosolic localization of antigens only occurs in special situations (e.g., 
infection of the DC itself with a virus or intracellular pathogen), this requirement would 
appear to strongly limit the occurrence of CD8+ T-cell responses in most settings. However, 
antigen loading onto class I MHC can also happen in a second circumstance: when DCs or 
macrophages phagocytose particulate antigen.237,238 Phagocytosis of antigen associated 
with dying cells, microparticles, or nanoparticles triggers professional APCs to shuttle a 
fraction of the antigen to the cytosol or to deliver it to special vacuoles where class I MHC 
loading can occur.239 This process, called cross presentation, was first demonstrated for 
antigens conjugated to synthetic iron oxide or polymer beads,240–243 but has since been 
demonstrated to occur for diverse synthetic particles composed of materials ranging from 
gold to calcium phosphate to solid polymers to hydrogels to lipids, and occurs irrespective 
of whether antigen is encapsulated in the particle or surface-conjugated.244–248 Although the 
earliest studies suggested an optimal particle size of several hundred nanometers for 
triggering cross presentation, more recent work has provided evidence for enhanced cross 
presentation of protein antigens conjugated to nanoparticles as small as 7–11 nm mean 
diameter.249,250 Efficient cross presentation leading to in vivo CD8+ T-cell expansion 
comparable to live viral infections has been reported with stabilized lipid nanocapsules 
termed ICMVs (interbilayer-crosslinked multilamellar vesicles)169,251 and also with 
multilamellar lipid vesicles loaded with a strong T-cell-inducing adjuvant (poly(I:C)) and 
surface-absorbed antigen.252 The ICMV technology has been licensed to Vedantra 
Pharmaceuticals, which aims to translate this nanocapsule approach to human clinical 
trials.253
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Although early studies covalently conjugated proteins to solid particles, cross presentation 
can be optimized by engineering particle-antigen linkages to be labile in the endosomal 
pathway. For example, antigen coupled to pluronic-stabilized poly(propylene sulfide) 
nanoparticles via a reduction-sensitive disulfide linkage specifically allowed for the release 
of antigen within the reductive environment of the endosome in APCs after uptake leading 
to enhanced in vitro and in vivo CD8+ T cell stimulation compared to non-degradable 
linkers.254,255 In pulmonary vaccination, these nanoparticles efficiently promoted cross 
presentation resulting in a 10-fold enhanced effector CD8+ T-cell frequency in the lungs.176 
Stano et al. carried out a comparative study of vaccination with antigen conjugated to 30 nm 
solid poly(propylene sulfide) (PPS) nanoparticles vs. the same antigen encapsulated in 125 
nm PPS-based polymersomes (Fig. 17).256 While PPS NPs promoted robust CD8+ T-cell 
responses, polymersomes with encapsulated antigen induced enhanced frequencies of 
antigen-specific CD4+ T cells in the spleen, lymph nodes, and lungs, but were inefficient at 
promoting CD8+ T-cells in comparison to solid nanoparticles.256 pH-sensitive micelles 
carrying antigen and adjuvant have also been utilized to enhance cross presentation to CD8+ 
T-cells, improving both cellular and humoral responses.257,258
Nanoparticles have also been demonstrated to have potential as platforms for cross 
presentation of complex antigen mixtures in DCs, as exemplified by the entrapment of 
tumor lysate proteins, leading to enhanced tumor-specific CD8+ T-cell priming relative to 
soluble lysate mixtures.259 Novel strategies for displaying antigens on nanoparticles also 
have great potential for enabling more effective cross presentation to T-cells. For example, 
Fang et al. developed a method to coat biodegradable polymer nanoparticles with 
membranes derived from tumor cells.260 This approach promoted antigen uptake and cross 
presentation by dendritic cells to tumor antigen-specific T-cells, and is especially attractive 
because it in principle allows the entire repertoire of tumor cell surface antigens to be 
delivered to DCs. This approach can also be used to directly target tumor cells and 
vasculature for immunotherapies.261 Alternatively, the delivery of minimal peptides has 
been shown to help avoid tolerance and T-cell mediated anergy by minimizing peptide 
loading on unintended class I MHC expressing cells.139,262–264
The strategies discussed above all rely on an intrinsic pathway for delivery of antigen to 
class I MHC following uptake of particulate antigen, which seems to be largely independent 
of particle chemistry and only weakly sensitive to particle size. However, nanoparticles can 
also promote cross presentation more directly following internalization, via endosome/
phagosome disruption and direct delivery of antigen to the cytosol, where they can be 
processed by the normal MHC I loading pathways. For this approach, most if not all of the 
common strategies employed for cytosolic drug delivery have been applied to promote 
antigen cross presentation. For example, Hu et al. developed core-shell gel nanoparticles 
with a pH-responsive core and nontoxic hydrophilic shell capable of efficient cytosolic 
delivery of membrane impermeable molecules via endosomal disruption through the proton 
sponge effect (studied for many years in nucleic acid delivery materials).265 When loaded 
with OVA protein these particles were shown to promote priming of CD8+ T-cells at 100-
fold lower doses compared to soluble protein.266 Going a step further to promote efficient 
antigen release from particles in the cytosol, bioreducible alginate-poly(ethylene imine) 
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nanogels carrying protein antigen have been synthesized. These particles were designed to 
disrupt endosomes through the proton sponge effect of PEI, and subsequently dissolve in the 
reducing conditions of the cytosol.267 These nanogels more strongly promoted intracellular 
antigen degradation and cytosolic release, robustly enhancing antibody responses and 
increased tumor cell lysis in an in vitro CD8+ T-cell cytotoxicity assay compared to non-
reducible nanogels.267 Endosomolytic and pH-responsive micelles additionally have the 
capability to uniformly surface display antigen and incorporate adjuvant.257,258 These 
micelles demonstrated enhanced cross-presentation in vitro and in vivo as a function of 
micelle-mediated enhancements in intracellular antigen retention and cytosolic antigen 
accumulation. Surface-engineered gold nanorods268 and acetylated dextran nanoparticles269 
have similarly been shown to osmotically rupture endosomes to deliver antigen to the 
cytosol. Intracellular targeting of the endoplasmic reticulum (ER) is another approach that 
has been shown to promote cross-presentation- following ER-endosome fusion nanoparticles 
are shuttled to the cytosol.270,271 Polymer-modified liposomes that destabilize at low pH 
have also been reported to mediate efficient cytosolic delivery of its cargo via endosome 
fusion and disruption.272,273 Additionally, one could imagine direct endosome destabilizing 
techniques to be applied to nanoparticle-mediated antigen delivery to the cytosol. For 
example, photochemical destabilization of endosomes for cytosolic delivery has been shown 
for antigens co-delivered with a photosensitizer that will cause a series of reactions to 
rupture endosomes upon light exposure to significantly enhance cross-presentation 
compared to soluble antigen alone.274
4.1.3 Modulating antigen presentation to invariant natural killer T-cells—While 
most cells of the adaptive immune system recognize foreign protein antigens, a subset of T-
cells known as invariant natural killer T (iNKT) cells have evolved to recognize lipid 
antigens presented by CD1d receptors expressed on APCs. A potent lipid antigen that 
stimulates iNKT cells is the glycolipid α-galactosylceramide (α-GalCer), and this molecule 
has been proposed as an adjuvant compound to trigger anti-viral and anti-tumor responses 
from iNKT cells. Analogous to “normal” T-cell activation, α-GalCer and other lipid ligands 
for iNKT cell receptors must be captured and presented to the iNKT cells on the non-
classical MHC molecule CD1d at the surface of APCs. Intravenous injection of α-GalCer 
leads to iNKT hypo-responsiveness, which is believed to be due in part to the non-selective 
nature of APCs that capture and present α-GalCer to iNKT cells following systemic 
administration. This can be prevented by targeting α-GalCer to specific subsets of APCs to 
activate iNKT cells in the right context. Fernandez et al. co-targeted α-GalCer and the 
model antigen ovalbumin to DCs by packaging them in PLGA nanoparticles with surface-
conjugated anti-DEC205. This strategy allowed for maximal stimulation of iNKT cells as 
shown by increased cytokine release, expansion of antigen-specific CD8+ T-cells, and 
increased anti-Ova IgG titers. Furthermore, targeting of α-GalCer to CD8+ DCs abrogated 
the hypo-responsiveness of iNKT cells upon re-stimulation.275 Another method to target α-
GalCer to DCs is to target the C-type lectin receptors (CLRs) expressed on the surface of 
DCs. CLRs recognize mannose receptors at the end of carbohydrate ligands and trigger 
phagocytosis. When α-GalCer is encapsulated in oligomannose-coated liposomes, these 
liposomes are preferentially taken up by dendritic cells resulting in enhanced iNKT 
activation and proliferation.276 Octaarginine or R8 is a cell-penetrating peptide, which when 
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attached to the surface of liposomes promotes uptake in dendritic cells by 
macropinocytocis.277 PEGylated R8-liposomes encapsulating α-GalCer were shown to elicit 
potent iNKT cell activation in vivo, resulting in prophylactic control of tumor cell 
growth.278
4.1.4 Targeting antigen to APCs and regulating kinetics of antigen release—A 
final function of nanoparticles in regulating T-cell responses is to regulate the availability of 
antigen in or around antigen presenting cells. Sustained exposure to antigen and, 
consequently, presentation on class I and II MHC complexes has been shown to promote 
prolonged CD4+ and CD8+ T cell activation and cytokine expression. Nanoparticles that 
encapsulate antigen for sustained release either in the extracellular environment or within 
DCs can promote T-cell responses. Shen et al. demonstrated enhanced and prolonged cross 
presentation of antigen loaded on PLGA nanoparticles in vitro relative to soluble antigen or 
antigen bound to latex beads.279 PLGA particles were able to facilitate endosomal escape of 
antigen into the cytosol and also served as an intracellular reservoir. In a more recent 
comparative study of PLGA nanoparticles and liposomes, Demento et al. demonstrated 
sustained release of antigen from PLGA nanoparticles resulted in enhanced recall of CD8+ 
T-cell responses following bacterial challenge, compared to fast-releasing liposomes (Fig. 
18).280 Furthermore, targeting moieties can be added to the surface of nanoparticles to 
directly engage cell-surface receptors on APCs and enhance uptake, effectively maximizing 
exposure to antigen.281 In addition, while sustained exposure to antigens in chronic 
inflammatory states, such as cancer, autoimmunity, and chronic inflammation, has been 
shown to induce tolerance and/or T cell exhaustion282,283, thus far there are no examples in 
the literature describing such undesirable effects from controlled antigen release by synthetic 
nanoparticles. This is likely due to several factors including (1) transient exposure to 
antigen, (2) antigen dose, and (3) the additional presence of a danger signal. In addition to 
the above examples, Hanlon et al. described how controlled released of tumor antigens from 
nanoparticles loaded onto dendritic cells can drive anti-tumor responses, while delivery of 
naked tumor lysate induced T cell profiles characteristic of tolerization and exhaustion.284
4.2 Nanoparticles as adjuvants
Complementary to their potential roles in presenting antigen to B-cells or delivering antigen 
to appropriate antigen processing pathways in antigen presenting cells, nanoparticles can 
also be designed to provide immunity- or tolerance-promoting secondary signals that are 
required to instruct the immune system as to the type of immune response to be mounted 
against the encountered antigen. In the former case, these immunity-promoting cues are 
often referred to as “danger signals”, as they are requisite cues that inform responding 
immune cells that a foreign antigen is dangerous (as opposed to being an innocuous 
environmental or food-derived antigen) and a protective immune response should be 
mounted.285 These are the cues needed for prophylactic or therapeutic vaccines. By contrast, 
counter-regulatory signals can be provided by nanoparticles that instruct the immune system 
to become tolerant to the encountered antigen. Such tolerizing signals could be used to block 
allergies, to counter xenoresponses to therapeutic proteins, or to treat autoimmune disease. 
Provision of these signals can be achieved in at least two ways: (i) nanoparticles can 
encapsulate compounds that stimulate the appropriate pro- or anti-immunity pathway, or (ii) 
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the nanoparticle itself, by virtue of its structure or composition, can itself stimulate these 
pathways. This section will discuss these two broad strategies for nanoparticle adjuvants.
4.2.1 Nanoparticle delivery of molecular adjuvants
Danger signals in the induction of the immune response: The danger signals that drive 
protective immunity in prophylactic or therapeutic vaccines are characterized as either (1) 
pathogen-associated molecular patterns (PAMPs; e.g. lipopolysaccharides or flagellin from 
bacteria, double-stranded RNA from viruses, or cell wall components from yeast and fungi) 
which are evolutionarily conserved molecular motifs unique to pathogens and absent from 
human tissue, or (2) so-called damage-associated molecular patterns (DAMPs; i.e. molecular 
signatures of tissue damage such as degraded heparan sulfate or uric acid released from 
dying cells).286,287 These compounds are recognized by pattern recognition receptors 
(PRRs) expressed by immune cells, especially antigen presenting cells, and instruct APCs to 
produce inflammatory cytokines and to up-regulate co-stimulatory receptors and antigen 
presentation machinery to produce productive T- and B-cell priming. The most well studied 
class of these receptors is the Toll-like receptors (TLRs). These natural components or 
synthetic compounds that act on their receptors are molecular adjuvants that can drive 
tailored immune responses through defined signaling pathways. Current evidence suggests 
that danger signaling is critical for an optimal immune response– adaptive immune 
responses to vaccines are dependent on danger signals.98,288–290 Even virus-like particles, 
despite their potent ability to engage B-cells as discussed above, are thought to rely on 
contaminating Toll-like receptor ligands for their immunogenicity.291
Enhancing molecular adjuvants through nanoparticle delivery: Nanoparticle delivery of 
molecular adjuvants can play several roles in vaccine design. The first is to enhance the 
potency and efficacy of adjuvants, through a number of distinct mechanisms. Nanoparticle 
delivery can concentrate adjuvants at a tissue level within lymphoid organs, forming 
intranodal depots and prolonging exposure in this important site of action (without 
necessarily eliciting toxic systemic exposure).131,146,153 This is especially relevant for 
small-molecule adjuvant compounds (e.g., imidazoquinolines that trigger TLRs 7 and 8), 
which are usually cleared rapidly to the bloodstream on injection. In the case of cytokines, 
which can also act as molecular adjuvants, it is essential to avoid systemic exposure. St. 
John et al. circumvented this issue by encapsulating various cytokines in synthetic mast-cell 
granule-like nanoparticles composed of chitosan and heparin that efficiently drained to 
lymph nodes and were able to effectively adjuvant vaccination with hemagglutinin.292 More 
recently, Hanson et al. showed a significant dose-sparing effect of cyclic dinucleotide small 
molecule adjuvants (agonists of cytosolic stimulator of IFN genes, STING) when loaded 
inside liposomal nanoparticles.293 Without compromising the humoral response towards the 
co-delivered antigen, systemic cytokine induction and toxicity was avoided.293 Such 
nanoparticle-mediated targeting of adjuvants to lymph nodes in vaccination increases both 
efficacy and safety, both by blocking systemic distribution of the adjuvant and by permitting 
significant dose-sparing (up to 250-fold).146,147,153,293,294 Targeted delivery of TLR ligands 
in nanoparticles to DCs has also been shown to strongly enhance adjuvanticity.295
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Particle encapsulation can also act to concentrate danger signals at the single cell level. As 
with antigens, nanoparticles’ natural tropism for phagocytic cells can concentrate adjuvants 
within receptor-bearing endosomal compartments or near the cell surface. Though the 
importance of local adjuvant concentration on danger signal receptor engagement and 
signaling has not yet been studied this is likely to play a role in the response to nanoparticle 
adjuvants. For example, co-encapsulation of TLR agonists and antigens in PLGA or calcium 
phosphate nanoparticles has been shown to enhance antigen uptake, APC activation, T-cell 
priming, and protection against infectious challenge in vivo.245,262,296,297 Co-encapsulation 
of antigen and adjuvant on nanoparticles also allows for co-localization of these compounds 
within the same endosomal/phagosomal compartments which has been shown to be a 
requirement for physically instructing dendritic cells to present the associated foreign 
antigen in vitro,298–300 although evidence exists for phagosome maturation in the absence of 
TLRs albeit at a slower constitutive rate.301,302 This was exemplified in the early 1990s by 
Friede et al. who compared TLR4 agonist, MPLA, delivery in the same or separate 
liposomes with peptide-antigen and found that MPLA delivered in the same nanoparticle 
resulted in significantly higher antigen-specific titers compared to delivery of MPLA in 
separate particles.115 Notably, several examples exist for which small nanoparticles at 
sufficient dosing can co-localize together in the same APC even if antigen and adjuvant are 
carried by separate particles, as illustrated by de Titta et al. for 30 nm poly(propylene 
sulfide) particles with surface-conjugated antigen mixed with particles functionalized with 
the TLR9 agonist CpG DNA.303
Nanoparticle delivery may also qualitatively change the biology of molecular adjuvants. For 
example, studies of adjuvants triggering the danger sensor TLR4 have suggested that TLR4 
signaling cannot provide a suitable danger signal for CD8+ T-cell responses.304 Early 
studies of TLR4 ligand (LPS) incorporation into empty liposomes also reported decreased 
LPS potency compared to soluble LPS in vitro.305 By contrast, TLR4 ligands co-
encapsulated with antigen in lipid nanoparticles have been shown to trigger robust cross 
presentation and CD8+ T-cell priming in vivo in mice.169 It is also known that combinations 
of danger signals can exhibit powerful synergy in activating APCs.306–308 Particle co-
encapsulation of combinations of danger signals provides the opportunity for maximizing 
this synergy. This has been dramatically illustrated with PLGA nanoparticles co-
encapsulating TLR4 and TLR7 small molecule adjuvants- co-delivery of these adjuvant 
compounds in PLGA resulted in a synergistic enhancement in comparison to either one of 
the TLR ligands delivered alone in separate particles (Fig. 19).309 Extremely long-lived 
germinal centers following vaccination were observed, resulting in high-titer and durable 
antibody responses. Importantly, these results have been recapitulated in non-human 
primates, setting the stage for clinical testing of this strategy for enhancing vaccines.309
Using nanoparticles to promote tolerance: In the absence of danger signals, the 
presentation of self-antigens on APCs can induce tolerance. One strategy to induce 
peripheral tolerance of auto-reactive T-cells is to intravenously inject fixed, self-antigen-
pulsed apoptotic splenocytes.310 This form of antigen delivery mimics the processing of 
self-antigens from dying host cells and results in the presentation of self-antigens on APCs 
in the absence of co-stimulatory signals. This therapy induces antigen specific tolerance of 
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T-cell clones and the generation of new regulatory T-cells.311 However, the requirement of 
manipulating live patient cells for this treatment makes this approach complex for clinical 
translation. Nanoparticle delivery of self-antigens to APCs has recently been investigated as 
an alternative strategy to promote tolerance.312 Hunter et al. employed biodegradable PLGA 
nanoparticles to systemically deliver antigens to APCs in the spleen. When PLGA particles 
conjugated with auto-antigenic peptides were administered intravenously, they prevented the 
onset of experimental autoimmune encephalitis (EAE), a model of human multiple sclerosis 
(MS) and further ameliorated the symptoms of established EAE.313 Another approach is to 
co-deliver auto-antigens together with immunoregulatory drugs that promote a tolerogenic 
response. PLGA nanoparticles delivering either peptide or protein antigens together with the 
Treg-promoting drug rapamycin inhibited CD4+ and CD8+ T-cell activation while 
increasing the number of regulatory T-cells.314 Selecta Biosciences, which is developing 
this platform, has successfully completed a phase I clinical trial of PLGA nanoparticle 
vaccines in a different indication315, demonstrating that these materials can be GMP 
manufactured for clinical translation of this strategy. Recently, nanogels carrying self-
antigens have shown superior tolerance induction compared to the delivery of soluble 
antigens or PLGA-loaded antigens, as a result of their increased internalization by 
DCs.316,317 Yeste et al. described a gold nanoparticle-based system that allowed for the co-
delivery of multiple factors to DCs that synergized to induce antigen-specific regulatory T-
cell activation leading to suppression of experimental autoimmune encephalomyelitis.318
The strategies just described all rely on targeting of antigens to APCs under conditions 
providing tolerogenic cues during antigen presentation to T-cells. Another approach is to 
directly deliver peptide-MHC ligands to T-cells via nanoparticles, in the absence of any 
other costimulatory signals. Tsai et al. demonstrated that peptide-MHC displaying 
nanoparticles could expand regulatory CD8+ T cells, a novel regulatory cell phenotype, and 
eventually restored normoglycemia in a humanized model of diabetes.319
Enhancing vaccine safety: Finally, the most critical issue with molecular adjuvants is 
safety. As noted above, a number of small-molecule danger signal compounds are 
problematic adjuvants for human use, due to their rapid dissemination into the systemic 
circulation on injection, leading to toxic systemic inflammation.146 Nanoparticle 
conjugation or encapsulation completely alters the fate of these compounds, promoting their 
targeting to lymphoid organs as discussed above, and blocking their trafficking into the 
systemic circulation. In addition, particle delivery may focus their action primarily on 
phagocytic cells (macrophages and dendritic cells) which may be beneficial for avoiding 
nonspecific polyclonal stimulation (e.g., of B-cells).
4.2.2 Intrinsic adjuvant properties of nanoparticles
Activating complement: The complement system – an ancient component of innate 
immunity – comprised of three distinct pathways (classical, lectin, and alternative), initiates 
a wealth of host responses including inflammatory responses which activate adaptive 
immunity and, thus, activation of complement may serve as an adjuvant strategy for 
vaccines and immunotherapeutics.320 While nanoparticles have been shown to be capable of 
activating complement, this is dependent on the surface chemistry of the particles.135,321–323 
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Reddy et al. reported that pluronic-stabilized poly(propylene sulfide) nanoparticles activated 
complement in a hydroxyl group-dependent manner and this activation induced the 
maturation of dendritic cells and enhanced cellular immunity when antigen was conjugated 
to the nanoparticles.135 Surface charge and carboxylation was later shown to further 
modulate complement activation.322 Alteration of the architecture of poly(ethylene oxide) 
chains on the surface of nanoparticles has also been shown to switch complement activation 
between classical and lectin pathways.323 The effects of this complement pathway switch on 
the adjuvant ability of nanoparticles remains to be elucidated.
Induction of autophagy: Recently it has begun to be recognized that nanoparticles may be 
capable of intrinsic adjuvant activity, deriving from their structure and/or composition, 
providing an entirely novel way for materials chemistry to be used to create new vaccines. 
One pathway for nanoparticle-mediated adjuvant action is induction of autophagy in antigen 
presenting cells. Autophagy is the process of “self-eating”– a process whereby cells engulf 
cytosolic contents into special membrane-bounded compartments known as 
autophagosomes, to degrade and recycle proteins during starvation or cellular stress. 
Autophagy is becoming recognized as an important player in diverse biological processes, 
including induction of the immune response.324 For example, Ravindran et al. recently 
demonstrated that virus-mediated signaling induced autophagy in dendritic cells, leading to 
enhanced CD4+ and CD8+ T-cell responses.325 This was the first study to demonstrate the 
link between the virus-induced integrated stress responses in DCs to the adaptive immune 
response. In parallel, studies of nanoparticle interactions with both tumor and normal cells 
have revealed that nanoparticle uptake can induce autophagy.326 Bringing these two 
observations together, Li et al. showed that alumina nanoparticles conjugated with antigen, 
which were shown to induce and, more importantly, require autophagy in dendritic cells to 
effectively cross present antigen to T cells, strongly promoted cellular and humoral immune 
responses in vivo.327
Activation of the inflammasome: A second pathway by which nanoparticles can directly 
provide danger signal effects is through activation of the inflammasome in APCs. 
Inflammasomes are cytosolic protein complexes that form in response to infection or stress, 
likely as a result of phagosomal/lysosomal rupture or destabilization, and further mediate 
inflammatory responses.328,329 Alum mediated adjuvancy has been correlated to activation 
of the NALP3 inflammasome in DCs,330,331 although some follow-up studies reported that 
the NALP3 inflammasome was not directly required for its adjuvant action.332,333 Similarly, 
other particulate vaccines have been demonstrated to activate the NALP3 inflammasome,334 
including PLGA335,336 and gold.337 Several groups have shown that the induction of 
immunity through activation of the inflammasome by solid particles is dependent on several 
particle characteristics including particle chemistry, size, and shape.337–339 Using a 
comprehensive library of aluminum-based nanoparticles, Sun et al. demonstrated that 
increased aspect ratio and surface hydroxyl content correlated with the extent of lysosome 
damage, inflammasome activation and IL-1β cytokine production.339 A study comparing 
various size and shape gold nanoparticles similarly revealed rod-like particles were the most 
effective inflammasome activators, although spherical and cubic particles significantly 
induced inflammatory cytokine production.337 Based on the collated evidence of diverse 
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particle types and chemistries triggering the inflammasome, it seems likely that the 
inflammasome may play a role in all nanoparticle-based vaccines.
Hydrophobicity as a danger signal: A third means for intrinsic adjuvant activity in 
nanomaterials is via hydrophobicity. Matzinger first proposed that the exposure of 
hydrophobic moieties, characteristic of unfolded proteins, microbes, and dying cells, could 
represent an important evolutionarily-conserved danger signal.340 Recently, evidence in 
support of this concept from synthetic nanoparticles has begun to emerge. Nanoparticles 
composed of amphiphilic poly(γ-glutamic acid) showed increased uptake and activation of 
DCs in vitro and cellular responses in vivo as a function of increased side-chain 
hydrophobicity.341 In agreement, increased surface hydrophobicity on gold nanoparticles 
has been shown to directly correlate to increased inflammatory cytokine expression levels 
both in vitro and in vivo.342 Petersen et al. demonstrated using amphiphilic polyanhydride 
nanoparticles that polymer hydrophobicity, in addition to several other factors including 
presentation of oxygen-rich molecular patterns and structural features, influenced innate 
immune responses.343
5 CONCLUSIONS
As shown by the many examples covered in this review, nanoparticle technologies offer a 
great breadth of new ways to tune specific immune responses for prevention or treatment of 
disease. Many of these new strategies for vaccines and immunotherapy were inspired by the 
availability of novel nanomaterials with new functionalities and capabilities. This trend 
should continue for the foreseeable future as many classes of new materials have yet to be 
studied in depth and may have great potential in this field. Examples include DNA 
nanostructures that can present complex, three-dimensional multivalent motifs to engage and 
organize immune cell receptors344–346, nanoparticles with the capacity to embed within or 
penetrate cell membranes347,348, and novel self-assembling materials that can form 
complex, hierarchical nanoparticles.349–351 While still in its infancy, the field of immune 
engineering, with nanoparticle technologies as key tools, is moving rapidly with a number of 
technologies moving beyond small animal models to non-human primate testing or other 
large animal models and small early-stage clinical trials.121,309,352–356 Important lessons for 
this effort can be gleaned from the field of cancer nanotechnology, chief among these being 
the importance of manufacturing– elegant materials that cannot be produced reliably or at 
large scale by commercial processes cannot survive the translation to clinical 
implementation. The availability of robust synthesis strategies must be a driving 
consideration right from the earliest stage of devising new concepts. These considerations 
will ensure that the field of synthetic nanoparticles for vaccines and immunotherapy reaches 
its full potential for clinical impact in public health and medicine.
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Figure 1. 
Examples of the impact of vaccination on disease burdens in the United States. (A) 
Poliomyelitis before and after introduction of the polio vaccines.12 Reprinted form reference 
12. (B) Measles cases before and after introduction of the measles vaccine.13 Reprinted from 
Center for Disease Control and Prevention: Vaccines and Immunizations Publications. 
Parents guide to childhood immunization http://www.cdc.gov/vaccines/pubs/parents-guide/
downloads/parents-guide-part3.pdf#page=10 (accessed Feb 1, 2015).
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Figure 2. 
Delivery of idinavir (IDV) nanoparticles loaded into bone marrow derived macrophages 
(BMDMs) results in increased serum and tissue drug concentrations. (A) Sections of spleen 
from mice at day 5 after the transfer of rhodamine-labeled idinavir nanoparticle loaded bone 
marrow derived macrophages (IDV-loaded BMDMs). Sections were stained for CD11b and 
examined by fluorescence microscopy. Higher magnification inserts demonstrate the co-
localization of BMDM-IDVs (Red) with the cytoplasm of CD11b+ cells (Green). BMDMs 
appear yellow in the merged panel and nuclei are stained in blue. (B–E) IDV distribution in 
targeted tissues and body fluids was assessed in mice treated with a single dose of (B) IDV 
free drug solution (C) Cell- free IDV nanoparticles (D–E) BMDM-IDVs. IDV 
concentrations in mice treated with BMDM-IDVs were increased and prolonged over 14 
days. Data represent mean ± SEM for n = 4 mice per group per time point. Magnifications 
are (originals) × 100 and (insets) × 400.37 Reprinted with permission from reference 37. 
Copyright 2006 American Society of Hematology.
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Figure 3. 
siRNA LNP is primarily engulfed in small vesicles by Kuppfer cells within the mononuclear 
cell pool. Representative images of cell stained with a surface lineage marker (Yellow), 
DAPI (Blue), and siRNA LNP (Red) are depicted (n = 3 per group). DAPI: 4’,6-
diamidno-2phenylindole; DC: Dendritic Cell; IU: Infectious Unit; KC: Kuppfer Cell; LNP: 
Lipidoid nanoparticle; LSEC: Liver Sinusoidal Endothelial Cell.52 Reprinted with 
permission from reference 52. Copyright 2013 American Society of Gene & Cell Therapy.
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Figure 4. 
Mannosylated liposomes are targeted to macrophages in the tumor microenvironement. (A) 
Schematic diagram of DOTA containing plain liposomes (B) Schematic diagram of DOTA 
containing mannosylated liposomes (Man-Lipos) (C and D) Strong fluorescence signal 
associated with PEG liposomes and Man-Lipos is localized to lung tumors. However, 
compared to Man-lipos, PEG liposomes exhibit a higher background signal and poor tumor 
contrast.63 Reprinted with permission from reference 63. Copyright 2012 Elsevier Ltd.
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Figure 5. 
Different nanoparticle based strategies to improve adoptive T-cell transfer (A) Schematic of 
iron-dextran nanoparticles functionalized with T-cell activating proteins (nano-APCs) 
stimulating T-cell receptor signaling in the absence or presence of a magnetic field (B) 
Adoptive transfer of magnet-enhanced nano-APC activated T cells increased survival 
compared to no magnet and control groups. Mice were censored if dead or tumors were > 
150 mm2. (p<0.001 by Mantel Cox log-rank test)74 Reprinted with permission from 
reference 74. Copyright 2014 American Chemical Society. (C) Schematic of maleimide-
based conjugation to cell surface thiols. MBP-PE: 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[4– (p-maleimidophenyl)butyamide] (D) Confocal microscopy 
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images of CD8+ effector T-cells immediately after conjugation with fluorescent 1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine (DiD)-labeled multilamellar lipid 
nanoparticles (top) and after 4 days of in vitro expansion (bottom) (D) Scale bar, 2 µm (E) 
Survival of mice after adoptive T-cell therapy is enhanced with nanoparticle conjugated T-
cells illustrated by Kaplan-Meir curves (n=6 per group)79 Reprinted with permission from 
reference 79. Copyright 2010 Nature America, Inc. (F) T-cell targeted liposome with surface 
attached anti-Thy1.1 or IL-2Fc (G) Representative histograms of liposomes labeling 
antigen-specific adoptively transferred or endogenous CD8+ T-cells 48 hours after adoptive 
transfer and 24 hours after liposome injection.83 Reprinted with permission from reference 
83. Copyright 2013 Elsevier B.V.
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Figure 6. 
Antigens bound to the surface of liposomes generate a significantly higher antibody tire. 
Mice were immunized with liposomes containing 2 µg MPLA associated with peptide. (a) 
no peptide (b) 60 µg peptide internally encapsulated in 5 µmol lipid (c) 65 µg peptide 
internally encapsulated in 1 µmol lipid (d) 60 µg peptide covalently bound to liposome 
surface (I µmol lipid) (e) 60 µg peptide co-injected with liposomes (1 µmol lipid) to which 
no peptide is bound (f) peptide conjugated to ovalbumin in Freund’s complete adjuvant with 
boosters in Freund’s incomplete adjuvant. IgG titer was measured after the third injection 
with an interval of three weeks between each injection.115 Reprinted with permission from 
reference 115 Copyright 1993 Pergamon Press Ltd.
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Fig. 7. 
Relationship between molecular weight and uptake into lymphatics following subcutaneous 
injection for a series of globular proteins and small molecules in a sheep model. Data for 
fluorodeoxyuridine (FuDu), inulincytochrome (CyC), interferon-α (IFN), human growth 
hormone (hGH), soluble insulin, r metHu-Leptin (Lep), an analogue of Leptin (Lep*), 
epoietin alfa (EPO), darbepoetin alfa (DA) and a high molecular weight protein (HMwP) 
Reproduced from Kaminska and Porter133 with permission. Reprinted with permission from 
reference 133. Copyright 2011 Elsevier B.V.
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Figure 8. 
Vaccination with PLGA-αCD40 nanoparticles prolong survival after tumor inoculation. 
Vaccines consisted of immunization in the right flank with 10 µg OVA encapsulated in 
nanoparticles displaying αCD40 mAb (NP-CD40), or isotype control antibody (NP-iso) at 7 
days prior to tumor inoculation in the prophylactic model (A), or 7 and 17 days post-tumor 
inoculation in the therapeutic model (B). Tumor inoculations consisted of 2×105 B16-OVA 
tumor cells injected s.c. in the left flank. Adapted from Rosalia et al.156 Reprinted with 
permission from reference 156. Copyright 2014 Elsevier Ltd.
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Figure 9. 
Nanoparticles targeted to lung DCs enhance vaccine uptake and protect against infection 
challenge. (A & B) C57BL/6 mice were immunized intratracheally with OVA in lipid 
nanoparticle (ICMV) or soluble formulations. Representative cryosections after intratracheal 
immunization with fluorescent OVA (red) from lungs on day 1 (A; scale bars, 50 µm) and 
mediastinal draining lymph nodes (mdLNs) on day 4 (B; scale bars, 200 µm). (C) C57BL/6 
mice were immunized intratracheally or subcutaneously with a peptide vaccine in 
nanoparticle (ICMV) or soluble forms on days 0 and 28, then challenged by intratracheal 
administration of vaccinia virus (1×106 PFU) on day 42; body weight changes were tracked 
over time. Adapted from Li et al.169 Reprinted with permission from reference 169. 
Copyright 2013 American Association for the Advancement of Science.
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Figure 10. 
Cationic nanogels facilitate effective delivery of vaccine antigen into the nasal mucosa. 
Antigen (Clostridium botulinum type-A neurotoxin BoHc/A) was administered intranasally 
in cationic nanogels (cCHP-BoHc/A) or in soluble form (BoHc/A) and nasal epithelium 
tissue sections were collected over time. Green fluorescence refers to the antigen, BoHc/A, 
red fluorescence refers to the nanogels, and nuclei are represented in blue. Adapted from 
Nochi et al.172 Reprinted with permission from reference 172. Copyright 2010 Macmillan 
Publishers Ltd.
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Figure 11. 
Carbon nanoparticles for oral vaccination. (A) Schematic of carbonization mechanism for 
formation of mesoporous carbon nanoparticles (C1). (B) Mean serum anti-BSA IgG profile 
of mice after: i.m. administration of BSA emulsified in Complete Freund’s Adjuvant (FCA), 
oral administration of soluble BSA, or oral administration of BSA loaded in carbon 
nanoparticles (C1). Prime and boost immunizations were spaced three weeks apart. Adapted 
from Wang et al.193 Reprinted with permission from reference 193. Copyright 2011 Elsevier 
B.V.
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Figure 12. 
Distribution of solid lipid nanoparticles (SLN) and PEGylated solid lipid nanoparticles 
(pSLN) in small intestinal villi viewed at different magnifications. Blue fluorescence 
indicates the nuclei of small intestinal cells and green fluorescence indicates nanoparticles. 
Adapted from Yuan et al.209 Reprinted with permission from reference 209. Copyright 2013 
American Chemical Society.
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Figure 13. 
MPPs are retained in the cervicovaginal tract. (A) Overlay of particle fluorescence intensity 
and photographic images for conventional nanoparticles (CPs) and mucus-penetrating 
particles (MPPs) in the entire cervicovaginal tract tissue. (B) Percent of particles remaining 
over time on the basis of quantification of particle fluorescence in (A). Adapted from Ensign 
et al.219 Reprinted with permission from reference 219. Copyright 2012 American 
Association for the Advancement of Science.
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Figure 14. 
Anti-OVA mouse serum IgG response to 100 µg OVA in ddy mice (n = 5 mice) after 
transcutaneous application of OVA in S/O nanodispersions or in PBS with (+) or without (-) 
polyarginine (R6), or OVA and R6 in separate nanodispersions (OVA S/O and R6 S/O), 
compared to subcutaneous injection of 100 µg soluble OVA in PBS. Adapted from Kitaoka 
et al.227 Reprinted with permission from reference 227. Copyright 2013 Elsevier B.V.
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Figure 15. 
A schematic view of antigen processing and presentation in dendritic cells (DCs). DC 
activity is initiated by pathogen-associated molecular patterns (PAMPs) and/or danger-
associated molecular patterns (DAMPs) that are recognized by pattern recognition receptors 
(PRRs) on the DC surface. As depicted on the right, antigen and adjuvant containing 
nanoparticles are internalized by DCs through cell internalization pathways such as 
phagocytosis. Exogenous antigen is processed by proteases in endocytic vesicles 
(endosomes) and eventually loaded onto MHC Class II molecules found in vesicles targeted 
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to endosomes that carry potential ligands. Once peptide is loaded onto MHC II molecules, 
the peptide-MHC II complex is trafficked to the cell membrane where it presents the antigen 
to CD4+ T-cells bearing a cognate T-cell receptor (TCR). Activated CD4+ T-cells can 
further initiate B-cell activation and other immune effector functions. Depicted on the left 
are the two alternate pathways through which antigens can be loaded onto MHC Class I 
molecules. In the classical MHC I loading pathway, cytosolic or endogenous antigens are 
processed through the proteasome. Resulting peptide fragments are transported to the 
endoplasmic reticulum (ER) where they are loaded onto MHC Class I molecules. In certain 
DCs, exogenous antigens can be loaded onto MHC Class I molecules (‘cross-presented’) 
when antigens from endosomes are released into the cytoplasm or when trafficked to special 
vacuoles (not depicted). Resulting peptide-MHC l complexes are similarly trafficked to the 
membrane where they can interact with CD8+ T-cells bearing cognate TCRs. Activated 
CD8+ T-cells have cytotoxic activity and can kill infected cells that present cognate peptide-
MHC I complexed antigens. DCs also express MHC Class I-like molecules called CD1d 
which present lipid antigens like a-galactosylceramide (a-Gal-Cer) to invariant TCRs on 
NKT cells. On the lower right side, nanoparticles carrying α-Gal-Cer are internalized, 
processed and lipid antigen is presented on CD1d to TCRs on NKT cells. NKT activation 
further leads to NK cell transactivation.
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Figure 16. 
Liposomes with surface-displayed B cell epitope (membrane-proximal external region, 
MPER) and encapsulated T-cell epitope (HIV30) promote strong B-cell responses against 
MPER while minimizing off-target responses against the helper epitope. (A) Schematic of 3 
forms of T-helper epitope incorporation in MPER liposomes. Only in the case of TCEP 
cleaved external HIV30 is the T-helper epitope displayed solely intrastructurally. (B) Mice 
were immunized with 150 nm MPER liposomes with soluble or incorporated HIV30 with 
co-delivered adjuvant-containing liposomes. Shown are serum anti-MPER and anti-HIV30 
IgG titers 7 days post-boost. Liposomes with “hidden” T helper HIV30 epitopes (cleaved 
HIV30) elicited greatly reduced antibody responses against the helper sequence. Adapted 
from Hanson et al.142 Reprinted with permission from reference 142. Copyright 2014 
Elsevier Ltd.
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Figure 17. 
(A) Schematic describing chemical and physical differences between solid-core NPs and 
water-core polymersomes (PS). Mice were immunized s.c. 3 times at 2-week intervals with 
various OVA formulations. One week after the final immunization, splenocytes, lymph 
nodes cells and lung leukocytes were isolated and restimulated ex vivo with OVA for 6 
hours. PSs were more effective than NPs in inducing cytokine-secreting CD4+ T-cells (B) 
while NPs were more effective in inducing cytokine-secreting CD8+ T-cells (C). Co-
administration of both particle types elicited T-cell immunity characteristic of the two 
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particles at the same time. Adapted from Stano et al.256 Reprinted with permission from 
reference 256. Copyright 2013 Elsevier Ltd.
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Figure 18. 
Sustained-release PLGA nanoparticles induce stronger immune responses than fast-release 
liposomes. (A) OVA release profiles from liposomes and PLGA nanoparticles incubated in 
PBS at 37°C. (B) Splenocytes from mice (n=3)—immunized subcutaneously on day 0 and 
challenged on day 90 with i.v. 5 ×104 CFU of OVA-expressing L. monocytogenes —were 
collected on day 7 post-challenge and pulsed with SIINFEKL. Activated antigen-specific 
CD8+CD44+ T-cells were determined using a SIINFEKL tetramer. Adapted from Demento 
et al.280 Reprinted with permission from reference 280. Copyright 2012 Elsevier Ltd.
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Figure 19. 
Immunization with two TLR agonists induces persistent germinal centers and long-lived 
antibody-forming cells in draining lymph nodes. C57BL/6 mice were immunized with OVA 
encapsulated in nanoparticles with TLR-4 agonist (MPL) and TLR-7 agonist (R837) plus 
antigen. (A) Antibody titers 4 weeks post-prime. (B) Germinal centers (GCs) were counted 
in draining lymph node (LN) sections over time. (C) ELISPOT assay quantification of 
antibody-secreting cells in lymph nodes over time. Adapted from Kasturi et al.309 Reprinted 
with permission from reference 309. Copyright 2011 Macmillan Publishers Ltd.
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Table 1
Synthetic nanoparticle characteristics for immunological applications
Nanomaterial Advantages Challenges Size
range
Refs
Gold nanoparticles • Inert, biocompatible
• Possess optical properties that 
can be used for diagnostic and 
photothermal applications
• Prolonged retention in 
hepatobiliary system (may 
lead to long-term toxicity)
• Non-biodegradable
10–100nm a, b
, 335
Carbon nanotubes • Ability to bind 
macromolecules like proteins 
and oligosaccharides so can 
act as antigen carriers
• Unique optical properties
• Require functionalization to 
ensure solubility and reduce 
cytotoxicty
• Some functionalized CNTs 
can cause activation of the 
innate immune system and 
inflammation
• Non-biodegradable
50–400nm c
, 230
Dendrimers • Enhanced drug solubility and 
bioavailability
• Multivalent surfaces to carry 
ligand molecules
• Flexibility of design
• Ease of handling
• Low cost
• High molecular weight 
dendrimers have limited 
tissue permeability
• High generation amino 
dendrimers cause 
inflammation and 
complement activation
10–30nm d
, 131
Solid polymer particles • Wide range of tunable surface 
properties depending on 
polymer selection and 
functionalization
• Highly versatile in size and 
aspect ratio
• Potential for high drug/ 
antigen loading
• Degradation products may be 
inflammatory
• Encapsulation likely to lead to 
antigen degradation
• Generally difficult to produce 
monodisperse preps without 
additional technologies (such 
as PRINT)
Varies e
, 139, 
254, 257
Polymer micelles • Self-assembly-based particle 
formation
• Small size for efficient tissue 
penetration
• Moderate drug loading
• Poor translation of micelle 
platforms between various 
protein antigen cargos
10–100nm e
, 256
Liposomes • Low immunogenicity
• High biocompatibility
• Antigen/immuno-modulator 
protection
• Versatile chemistry
• Poor stability
• Poor drug loading efficiency
30–200nm f, g
, 110
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